



AU9210707

(12) PATENT ABRIDGMENT (11) Document No. **AU-B-10707/92**
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. **655794**

(54) Title
BENZIMIDAZOLE COMPOUNDS

International Patent Classification(s)
(51)⁵ COTP 235108 A61K 031/44 A61K 031/47 A61K 031/60
C07D 401/14 C07D 403/10 C07D 403/12 C07D 403/14
C07D 417/14 C07D 471/04 C07D 487/04 C07D 513/04
A61K 031/415 A61K 031/445 A61K 031/505 A61K 031/535

(21) Application No. : **10707/92** (22) Application Date : **05.02.92**

(30) Priority Data

| (31) Number | (32) Date | (33) Country |
|-------------|-----------|--------------|
| 4103492 | 06.02.91 | DE GERMANY |
| 4117121 | 25.05.91 | DE GERMANY |
| 4137812 | 16.11.91 | DE GERMANY |

(43) Publication Date : **13.08.92**

(44) Publication Date of Accepted Application : **12.01.95**

(71) Applicant(s)
DR KARL THOMAE GMBH


(72) Inventor(s)
NORBERT HAUER; BERTHOLD NARR; UWE RIES; JACQUES VAN MEEL; WOLFGANG WIENEN; MICHAEL ENTZEROTH

(74) Attorney or Agent
CALLINAN LAWRIE „Private Bag 7, KEW VIC 3101

(56) Prior Art Documents
AU 53013/90 C07D
EP 400835

(57) Claim

1. Compounds of formula



(wherein

W, in the 4-position represents a fluorine, chlorine or bromine atom or a C₁₋₄-alkyl, cycloalkyl, fluoromethyl, difluoromethyl or trifluoromethyl group, and

R₂ represents a C₃₋₅-alkoxy group substituted in the 3-,

4- or 5-position by an **imidazolyl** group, or R_2 may represent a **C_{2,3}-alkoxy** group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

or R_2 represents a C_n-alkylsulphonyloxy group, a benzenesulphonyloxy or phenylalkanesulphonyloxy group,

an acylamino group optionally substituted at the nitrogen atom by a **C_{1,6}-alkyl** group or by a phenyl, cycloalkyl, phenylalkyl, **cycloalkylalkyl**, bicyclohexyl or biphenyl group, in which the acyl group is a C_{1,7}-alkanoyl group, a **C_{2,4}(alkoxycarbonyl)** group, a C_{1,6}-alkylsulphonyl group, a benzoyl, benzenesulphonyl, **phenylalkanesulphonyl**, **naphthalenesulphonyl**, cycloalkylcarbonyl, phenylalkanoyl or **cycloalkylalkanoyl** group, in which the above-mentioned phenyl nuclei may each be mono- or **di-substituted** by a fluorine, chlorine or **bromine** atom or by a methyl or methoxy group and the substituents may be identical or different,

a phthalimino, homophthalimino, 2-carboxyphenylcarbonylamino or 2-carboxyphenylmethylamino group, in which a carbonyl group in a phthalimino group may be replaced by a methylene, **alkyl-methylene** or dialkyl-methylene group, and a methylene group in a homophthalimino group may be substituted by one or two alkyl groups, and additionally **the** above-mentioned phenyl nuclei may be totally or **partially hydrogenated** and may be mono- or di-substituted by alkyl or alkoxy groups **whilst** the substituents may be identical or different,

a 5-, 6- or 7-membered **alkyleneimino** or **alkenyleneimino** group optionally substituted by one or two alkyl groups or by a **tetramethylene** or pentamethylene group, in which a methylene group may be replaced by a carbonyl or **sulphonyl** group,

a bicycloalkane-2,3-dicarboxylic acid imino or bicycloalkene-2,3-dicarboxylic acid imino group, wherein **the bicycloalkane and bicycloalkene moieties may each contain 9 or 10 carbon atoms, may be substituted by 1, 2 or 3 methyl groups and may have an endomethylene group replaced by an oxygen atom,**

an amidino group optionally substituted by one or **two C₁₋₆** alkyl groups,

a **glutaric** acid imino group wherein the n-propylene group may be perfluorinated, or may be substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group,

a **maleic** acid **imido** group optionally mono- or **di-**substituted **by** an alkyl **or** phenyl group, whilst the substituents may be identical or different,

a 5-membered heteroaromatic ring bound via a carbon atom or via an imino group and containing an imino group, an oxygen or sulphur atom, or an imino group plus an oxygen, sulphur or nitrogen atom, or **R₂ may represent a 6-membered** heteroaromatic ring bound via a carbon atom and containing 1 or 2 nitrogen atoms, whilst the abovementioned heteroaromatic rings may be substituted in **the** carbon structure by a **C₁₋₆** alkyl or by a phenylalkyl group, and an n-propylene **or** n-butylene **group** may be linked to the 6-membered heteroaromatic rings via two carbon atoms, or a **1,3-butadienyl** group may be linked to both the 5-membered and 6-membered heteroaromatic rings via two **adjacent** carbon **atoms** or an n-butylene or **1,3-butadienyl** group **is** linked thereto **via** an **imino** group and an **adjacent** carbon atom and, in an **anellated** pyridine ring thus **formed**, a methine group may be replaced by a **nitrogen** atom and a vinylene group in **the** 3-, 4-**position** relative to the nitrogen atom of the

pyridine ring formed may be replaced by a sulphur atom or in an anellated phenyl ring thus formed, one or two methine groups may be replaced by N-atoms, whilst additionally the above-mentioned fused aromatic or heteroaromatic rings may be monosubstituted in the carbon structure by a fluorine, chlorine or bromine atom or by an alkyl, alkoxy, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, alkanoyl, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group or may be disubstituted by fluorine or chlorine atoms or by methyl, methoxy or hydroxy groups, and two methyl substituents in the 1,2-position relative to each other may be linked by a methylene or ethylene bridge and an -NH- group optionally present in an imidazole ring may be substituted by a C₁₋₆-alkyl group, by a phenylalkyl group or by a cycloalkyl group, or

a pyrrolidine, piperidine or pyridine ring bound via a carbon atom, in which a phenyl group may be condensed onto the pyridine ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group,

.an imidazolidinedione group optionally substituted by an alkyl, phenylalkyl, tetramethylene, pentamethylene or hexamethylene group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by an optionally phenyl substituted alkyl group and additionally, in the carbon skeleton, by 1 or 2 alkyl groups,

an R₇-NR₆-CO-NR₅- group

(wherein

R_5 represents a hydrogen atom or a C_{1-8} -alkyl, C_{5-7} cycloalkyl or phenylalkyl group,

R_6 represents a hydrogen atom or a C_{1-8} -alkyl, C_{3-5} -alkenyl, phenyl, phenylalkyl or C_{5-7} -cycloalkyl group,

R_7 represents a hydrogen atom or a C_{1-6} -alkyl group, or

one of the groups R_5 , R_6 or R_7 may also represent a bicyclohexyl or biphenyl group, or

R_6 and R_7 together with the nitrogen atom between them represent an unbranched C_{4-6} -alkyleneimino group or a morpholino group, or

R_5 and R_6 together represent a C_{2-4} -alkylene group),

or R_2 may represent a 1H,3H-quinazolin-2,4-dion-3-yl or pentamethylene-oxazolin-2-yl group,

or, if R_4 represents a 1H-tetrazolyl group, R_2 may also represent a 2-(imidazol-1-yl)-ethoxy group; or

R_1 ~~represents~~ a hydrogen atom or in the 5-, 6- or 7-position R_1 represents a fluorine, chlorine or bromine atom or a C_{1-4} -alkyl, fluoromethyl, difluoromethyl or trifluoromethyl group, and

R_2 represents a 5-membered heteroaromatic ring bound via a carbon atom or via an imino group and containing an imino group, an oxygen or sulphur atom or, an imino group plus an oxygen, sulphur or nitrogen atom, or R_2 represents a 6-membered heteroaromatic ring bound via a carbon atom and containing 1 or 2 nitrogen atoms, whilst the above mentioned heteroaromatic rings may be

(11) AU-B-10707/92
(10) 655794

-6-

substituted in the carbon skeleton by a C_{1-6} alkyl or by a phenylalkyl group and an n-propylene or n-butylene group may be linked **to** the 6-membered heteroaromatic rings via **two** carbon atoms, or a **1,3-butadienyl** group may be linked via **two adjacent** carbon atoms to both the **5-membered and 6-membered heteroaromatic** rings or an **n-butylene** or **1,3-butadienyl** group may be linked to **said** 5-membered and 6-membered heteroaromatic rings via an **imino** group and an **adjacent** carbon atom and, in an anellated pyridine ring thus formed, a methine group may be replaced by a nitrogen atom and a vinylene group in the 3-, 4-position relative to the nitrogen atom of the pyridine ring formed may be replaced by a sulphur atom or in an anellated phenyl ring thus formed, one or two methine groups may be replaced by N-atoms, whilst additionally the above-mentioned fused aromatic or heteroaromatic rings may be monosubstituted on the carbon skeleton by a fluorine, chlorine or **bromine atom** or by an alkyl, alkoxy, hydroxy, phenyl, nitro, **amino**, alkylamino, dialkylamino, **alkanoylamino**, cyano, carboxy, alkoxy carbonyl, aminocarbonyl, alkylarninocarbonyl, dialkylaminocarbonyl, fluoromethyl, **difluoromethyl**, trifluoromethyl, alkanoyl, **aminosulphonyl**, alkylaminosulphonyl or **dialkylamino-sulphonyl** group or may be disubstituted by fluorine or chlorine atoms or by **methyl**, methoxy or hydroxy groups, and two **methyl** substituents in the **1,2-position** relative to each other may be linked by a **methylene** or ethylene **bridge** and an -NH- group optionally present in an **imidazole** ring may be substituted by a C_{1-6} -alkyl group, by a phenylalkyl group or by a cycloalkyl group, with the provisos that where

- (i) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy, **tert.butoxycarbonyl**, cyano or **1H-tetrazolyl** group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where *

- (ii) R_1 represents a hydrogen atom, R_3 represents a methyl, ethyl or n-butyl group and R_4 represents a cyano or 1H-tetrazolyl group, then R_2 cannot represent a benzoxazol-2-yl or 1-methyl-benzimidazol-2-yl group in the 6-position, and where
- (iii) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy or tert.butoxycarbonyl group, then R_2 cannot represent a benzimidazol-2-yl group in the 6-position, and where
- (iv) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy or tert.butoxycarbonyl group, then R_2 cannot represent a 3-methyl-imidazo-[4,5-b]pyridin-2-yl or 3-n-hexyl-imidazo[4,5-b]pyridin-2-yl group in the 6-position, a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a methyl or trifluoromethyl group, by a fluorine or chlorine atom or in the 6-position by a methyl group, or a 1-n-butyl-benzimidazol-2-yl group in the 6-position, and where
- (v) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a bromine atom or by a methoxy group, a 1-n-butyl-5-trifluoromethyl-benzimidazol-2-yl or 1-n-hexyl-5-methyl-benzimidazol-2-yl group in the 6-position, and where
- (vi) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a carboxy or tert.butoxycarbonyl group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position,

or R_2 may represent a pyrrolidine, piperidine or pyridine ring bound **via a carbon atom**, in which a phenyl group **may** be condensed onto the pyridine ring via 2 adjacent carbon atoms and a **methylene** group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group;

R_3 represents a hydrogen atom or a **C₁₋₅-alkyl** group in which a methylene group may be replaced by a sulphur atom, or R_3 may represent a **C₃₋₅cycloalkyl** group; and R_4 represents a **carboxy**, cyano, **1H-tetrazolyl**, 1-triphenylmethyldetrazolyl, **C₂₋₅(alkoxycarbonyl)**, alkanesulphonylamino-carbonyl, arylsulphonylamino-carbonyl or trifluoromethanesulphonylamino-carbonyl **group**;

wherein, unless otherwise **specified**, each alkanoyl, **alkyl** or **alkoxy** moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms)

and the isomers, isomer **mixtures** and addition salts thereof.

10. A method of **treatment** of the human or non-human **animal** body said **method** comprising administering to said body a pharmaceutically acceptable form of a **compound** of formula I as defined in any one of **claims** 1 to 7 or an isomer or salt thereof.

11. A method of treatment as **claimed** in **claim** 10 wherein said body **is** suffering from hypertension, **pulmonary** diseases, cardiac insufficiency, ischaemic peripheral circulatory disorders, myocardial ischaemia (**angina**), diabetic nephropathy, **glaucoma**, gastrointestinal or bladder diseases or cardiac **insufficiency after** myocardial infarction.

655794

AUSTRALIA

PATENTS ACT 1990

COMPLETE SPECIFICATION

FOR A STANDARD PATENT

ORIGINAL



TO BE COMPLETED BY APPLICANT



Name of Applicant:

DR KARL THOMAE GmbH



Actual Inventors:

**Norbert Hael; Berthold Narr; Uwe Ries; Jacques Van Meel; Wolfgang
Wienen; Michael Entzeroth**

Address for Service:

CALLINAN LAWRIE, 278 High Street, Kew, 3101, Victoria, Australia

Invention Title:

"BENZIMIDAZOLE COMPOUNDS"

**The following statement is a full description of this invention, including the best method of
performing it known to me:-**


Benzimidazole Compounds

The present invention is concerned with benzimidazole compounds, the isomers and salts thereof, which are useful pharmaceutically and especially as angiotensin antagonists.

The new benzimidazoles of the present invention are suitable for the treatment of hypertension and cardiac insufficiency and also for treating ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), for the prevention of the progression of cardiac insufficiency after myocardial infarction and for treating diabetic nephropathy, glaucoma, gastrointestinal diseases and bladder diseases.

EP-A-0 392 317 has already described benzimidazoles which are valuable as angiotensin antagonists.

Viewed from one aspect, the present invention provides compounds of formula I



(wherein

R, in the 4-position represents a fluorine, chlorine or bromine atom, or a C₁₋₄-alkyl, a cycloalkyl, fluoromethyl, difluoromethyl or trifluoromethyl group, and

57636000.575

R_2 represents a C_{3-5} -alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R_2 may represent a C_{2-5} -alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

or R_2 represents a C_{1-4} -alkylsulphonyloxy group, a benzenesulphonyloxy or phenylalkanesulphonyloxy group,

an acylamino group optionally substituted at the nitrogen atom by a C_{1-6} -alkyl group or by a phenyl, cycloalkyl, phenylalkyl, cycloalkylalkyl, bicyclohexyl or bihenyl group, in which the acyl group is a C_{1-7} -alkanoyl group, a C_{2-4} (alkoxycarbonyl) group, a C_{1-6} -alkylsulphonyl group, a benzoyl, benzenesulphonyl, phenylalkanesulphonyl, naphthalenesulphonyl, cycloalkylcarbonyl, phenylalkanoyl or cycloalkylalkanoyl group, in which the above-mentioned phenyl nuclei may each be mono- or di-substituted by a fluorine, chlorine or bromine atom or by a methyl or methoxy group and the substituents may be identical or different,

a phthalimino, homophthalimino, 2-carboxyphenylcarbonylamino or 2-carboxyphenylmethylamino group, in which a carbonyl group in a phthalimino group may be replaced by a methylene, alkyl-methylene or dialkyl-methylene group, and a methylene group in a homophthalimino group may be substituted by one or two alkyl groups, and additionally the above-mentioned phenyl nuclei may be totally or partially hydrogenated and may be mono- or di-substituted by alkyl or alkoxy groups whilst the substituents may be identical or different

a 5-, 6- or 7-membered alkyleneimino or alkenyleneimino group optionally substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group, in which a methylene group may be replaced by a carbonyl or



sulphonyl group,

a bicycloalkane-2,3-dicarboxylic acid imino or bicycloalkene-2,3-dicarboxylic acid imino group, wherein the bicycloalkane and bicycloalkene moieties may each contain 9 or 10 carbon atoms, may be substituted by 1, 2 or 3 methyl groups and may have an endomethylene group replaced by an oxygen atom,

an amidino group optionally substituted by one or two C_{1-6} alkyl groups,

a glutaric acid imino group wherein the n-propylene group may be perfluorinated, or may be substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group,

a maleic acid imido group optionally mono- or di-substituted by an alkyl or phenyl group, whilst the substituents may be identical or different,

a 5-membered heteroaromatic ring bound via a carbon atom or via an imino group and containing an imino group, an oxygen or sulphur atom, or an imino group plus an oxygen, sulphur or nitrogen atom, or R_2 may represent a 6-membered heteroaromatic ring bound via a carbon atom and containing 1 or 2 nitrogen atoms, whilst the abovementioned heteroaromatic rings may be substituted in the carbon structure by a C_{1-6} alkyl or by a phenylalkyl group, and an n-propylene or n-butylene group may be linked to the 6-membered heteroaromatic rings via two carbon atoms, or a 1,3-butadienyl group may be linked to both the 5-membered and 6-membered heteroaromatic rings via two adjacent carbon atoms or an n-butylene or 1,3-butadienyl group is linked thereto via an imino group and an adjacent carbon atom and, in an anellated pyridine ring thus formed, a methine group may

be replaced by a nitrogen atom and a vinylene group in the 3-, 4-position relative to the nitrogen atom of the pyridine ring formed may be replaced by a sulphur atom or in an anellated phenyl ring thus formed, one or two methine groups may be replaced by N-atoms, whilst additionally the above-mentioned fused aromatic or heteroaromatic rings may be monosubstituted in the carbon structure by a fluorine, chlorine or bromine atom or by an alkyl, alkoxy, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, alkanoyl, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group or may be disubstituted by fluorine or chlorine atoms or by methyl, methoxy or hydroxy groups, and two methyl substituents in the 1,2-position relative to each other may be linked by a methylene or ethylene bridge and an -NH- group optionally present in an imidazole ring may be substituted by a C₁₋₆-alkyl group, by a phenylalkyl group or by a cycloalkyl group, or

a pyrrolidine, piperidine or pyridine ring bound via a carbon atom, in which a phenyl group may be condensed onto the pyridine ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group,

an imidazolidinedione group optionally substituted by an alkyl, phenylalkyl, tetramethylene, pentamethylene or hexamethylene group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by an optionally phenyl substituted alkyl group and additionally, in the carbon skeleton, by 1 or 2 alkyl groups,

an $R_7-NR_6-CO-NR_5-$ group

(wherein

R_5 represents a hydrogen atom or a C_{1-8} -alkyl, C_{5-7} cycloalkyl or phenylalkyl group,

R_6 represents a hydrogen atom or a C_{1-8} -alkyl, C_{3-5} -alkenyl, phenyl, phenylalkyl or C_{5-7} -cycloalkyl group,

R_7 represents a hydrogen atom or a C_{1-6} -alkyl group, or

one of the groups R_5 , R_6 or R_7 may also represent a bicyclohexyl or biphenyl group, or

R_6 and R_7 together with the nitrogen atom between them represent an unbranched C_{4-6} -alkyleneimino group or a morpholino group, or

R_5 and R_6 together represent a C_{2-4} -alkylene group),

or R_2 may represent a 1H,3H-quinazolin-2,4-dion-3-yl or pentamethylene-oxazolin-2-yl group,

or, if R_4 represents a 1H-tetrazolyl group, R_2 may also represent a 2-(imidazol-1-yl)-ethoxy group; or

R_1 represents a hydrogen atom or in the 5-, 6- or 7-position R_1 represents a fluorine, chlorine or bromine atom or a C_{1-4} -alkyl, fluoromethyl, difluoromethyl or trifluoromethyl group: and

represents a 5-membered heteroaromatic ring bound via a carbon atom or via an imino group and containing an imino group, an oxygen or sulphur atom or, an imino group plus an oxygen, sulphur or nitrogen atom, or R_2 represents a 6-membered heteroaromatic ring bound via a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100



carbon atom and containing 1 or 2 nitrogen atoms, whilst the **above** mentioned heteroaromatic rings may be substituted in the carbon skeleton by a **C₁₋₆** alkyl or by a phenylalkyl group and an n-propylene or **n-butylene** group may be linked to **the 6-membered** heteroaromatic **rings** via two carbon atoms, or a **1,3-butadienyl** group may be linked via two **adjacent** carbon atoms to both the 5-membered and 6-membered heteroaromatic rings or an **n-butylene** or **1,3-butadienyl** group may be linked to **said 5-membered** and 6-membered heteroaromatic rings via an imino group and an **adjacent** carbon atom and, in an anellated pyridine ring thus formed, a methine group may be replaced by a nitrogen atom and a vinylene group in the 3-, 4-position relative to the nitrogen atom of the pyridine ring formed may be replaced by a sulphur atom or in an anellated phenyl ring thus formed, one or two methine groups may be replaced by **N-atoms**, whilst **additionally** the above-mentioned fused aromatic or heteroaromatic rings may be monosubstituted on the carbon skeleton by a fluorine, chlorine or bromine atom or by an alkyl, **alkoxy**, hydroxy, **phenyl**, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, **alkoxycarbonyl**, aminocarbonyl, **alkylaminocarbonyl**, dialkylaminocarbonyl, **fluoromethyl**, difluoromethyl, **trifluoromethyl**, alkanoyl, aminosulphonyl, **alkylaminosulphonyl** or dialkylamino-sulphonyl group or may be **disubstituted** by fluorine or **chlorine** atoms or by methyl, **methoxy** or **hydroxy groups**, and two methyl substituents in the **1,2-position** relative to each other may be linked by a **methylene** or ethylene **bridge** and an -NH- group optionally present in an **imidazole** ring may be substituted by a **C₁₋₆-alkyl** group, by a **phenylalkyl** group or by a **cycloalkyl** group, with the provisos that **where**

- (1) **R₁** represents a hydrogen atom, **R₂** represents an n-propyl group and **R₄** represents a carboxy,



tert.butoxycarbonyl, cyano or **1H-tetrazolyl** group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where

- (ii) R_1 represents a hydrogen atom, R_3 represents a methyl, **ethyl** or n-butyl group and R_4 represents a cyano or **1H-tetrazolyl** group, then R_2 cannot represent a benzoxazol-2-yl or **1-methyl-beniimidazol-2-yl** group in the 6-position, and where
- (iii) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy or **tert.butoxycarbonyl** group, then R_2 cannot represent a benzimidazol-2-yl group in the 6-position, and where
- (iv) R_1 **represents** a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy or **tert.butoxycarbonyl** group, then R_2 cannot represent a 3-methyl-imidazo-[4,5-b]pyridin-2-yl or 3-n-hexyl-imidazo[4,5-b]pyridin-2-yl group in the 6-position, a 1-methyl-benzimidazol-2-yl **group** in the 6-position substituted in the 5-position by a methyl or trifluoromethyl group, by a **fluorine** or **chlorine** atom or in the 6-position by a methyl group, or a 1-n-butyl-benzimidazol-2-yl group in the 6-position, and where
- (v) R_1 **represents** a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a **carboxy** group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl **group** in the 6-position substituted in the 5-position by a bromine atom or by a methoxy group, a **1-n-butyl-5-trifluoromethyl-benzimidazol-2-yl** or 1-n-hexyl-5-methyl-benzimidazol-2-yl group in the 6-position, and where



(vi) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a carboxy or **tert.butoxycarbonyl** group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position,

or R_2 may represent a pyrrolidine, piperidine or pyridine ring bound via a carbon atom, in which a phenyl group may be **condensed** onto the pyridine ring **via 2 adjacent** carbon atoms and a methylene group **adjacent** to **the** N-atom in a pyrrolidine or piperidine ring may be replaced by a **carbonyl** group;

R_3 represents a hydrogen atom or a **C₁₋₅-alkyl** group in

100

100



which a methylene group may be replaced by a sulphur atom, or R_3 may represent a C_{3-7} cycloalkyl group, and

R_4 represents a carboxy, cyano, 1H-tetrazolyl, 1-triphenylmethyldetrazolyl, C_{2-5} (alkoxycarbonyl), alkanesulphonylamino carbonyl, arylsulphonylamino carbonyl or trifluoromethanesulphonylamino carbonyl group;

wherein, unless otherwise specified, each alkanoyl, alkyl or alkoxy moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms)

and the isomers, isomer mixtures and addition salts thereof, in particular the 1,3-isomer mixtures and, for pharmaceutical use, the physiologically acceptable addition salts with inorganic or organic acids or bases.

The groups R_1 , R_2 and R_3 may for example represent the following:

R_1 may represent a hydrogen, fluorine, chlorine or bromine atom or a methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyl, 1-methyl-n-propyl, 2-methyl-n-propyl, tert.butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, fluoromethyl, difluoromethyl or trifluoromethyl group;

R_2 may represent a 3-(imidazol-1-yl)propoxy, 4-(imidazol-1-yl)butoxy, 5-(imidazol-1-yl)pentoxy, 2-(benzimidazol-1-yl)ethoxy, 3-(benzimidazol-1-yl)-propoxy, 4-(benzimidazol-1-yl)butoxy, 5-(benzimidazol-1-yl)-pentoxy, 2-(tetrahydrobenzimidazol-1-yl)ethoxy, 3-(tetrahydrobenzimidazol-1-yl)propoxy, 4-(tetrahydrobenzimidazol-1-yl)butoxy, 5-(tetrahydrobenzimidazol-1-yl)pentoxy, methanesulphonyloxy, ethanesulphonyloxy, n-propanesulphonyloxy, isopropanesulphonyloxy, n-

butanesulphonyloxy, benzenesulphonyloxy, 4-fluorobenzenesulphonyloxy, 4-bromobenzenesulphonyloxy, 4-methylbenzenesulphonyloxy, 4-methoxybenzenesulphonyloxy, 3,4-dichlorobenzenesulphonyloxy, phenylmethanesulphonyloxy, 2-phenylethanesulphonyloxy, 3-phenylpropanesulphonyloxy, formylamino, acetylamino, propionylamino, butanoylamino, isobutanoylamino, pentanoylamino, 3-methyl-butanoylamino, hexanoylamino, methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino, methane-sulphonylamino, ethanesulphonylamino, n-propanesulphonylamino, isopropanesulphonylamino, n-butanesulphonylamino, n-pentanesulphonylamino, n-hexanesulphonylamino, benzamido, benzenesulphonylamido, 4-fluorobenzenesulphonamido, 4-chlorobenzenesulphonamido, 4-bromobenzenesulphonamido, 4-methylbenzenesulphonamido, 4-methoxybenzenesulphonamido, phenylmethanesulphonylamido, 2-phenylethanesulphonylamido, 3-phenylpropanesulphonylamido, naphthalen-1-yl-sulphonamido, naphthalen-2-yl-sulphonylamido, cyclopentylcarbonylamido, cyclohexylcarbonylamido, cycloheptylcarbonylamido, phenylacetylamido, 3-phenylpropionylamido, cyclopentylacetylamido, 3-cyclopentylpropionylamido, cyclohexylacetylamido, 3-cyclohexylpropionylamido, cycloheptylacetylamido, 3-cycloheptylpropionylamido, N-methyl-formylamino, N-methyl-acetylamino, N-methyl-propionylamino, N-methyl-butanoylamino, N-methyl-isobutanoylamino, N-methyl-pentanoylamino, N-methyl-3-methyl-butanoylamino, N-methyl-hexanoylamino, N-methyl-methoxycarbonylamino, N-methyl-ethoxycarbonylamino, N-methyl-n-propoxycarbonylamino, N-methyl-isopropoxycarbonylamino, N-methyl-methanesulphonylamino, N-methyl-ethanesulphonylamino, N-methyl-n-propanesulphonylamino, N-methyl-isopropanesulphonylamino, N-methyl-n-butanesulphonylamino, N-methyl-n-pentanesulphonylamino, N-methyl-n-hexanesulphonylamino, N-methyl-benzamido, N-methyl-benzenesulphonylamido, N-methyl-4-fluorobenzene-

sulphonamido, N-methyl-4-chlorobenzenesulphonamido, N-methyl-4-bromobenzenesulphonamido, N-methyl-4-methylbenzenesulphonamido, N-methyl-4-methoxybenzenesulphonamido, N-methyl-phenylmethanesulphonylamido, N-methyl-2-phenylethanesulphonylamido, N-methyl-3-phenylpropanesulphonylamido, N-methyl-naphthalen-1-yl-sulphonamido, N-methyl-naphthalen-2-yl-sulphonylamido, N-methyl-cyclopentylcarbonylamido, N-methyl-cyclohexylcarbonylamido, N-methyl-cycloheptylcarbonylamido, N-methyl-phenylacetylamido, N-methyl-3-phenylpropionylamido, N-methyl-cyclopentylacetylamido, N-methyl-3-cyclopentylpropionylamido, N-methyl-cyclohexylacetylamido, N-methyl-3-cyclohexylpropionylamido, N-methyl-cycloheptylacetylamido, N-methyl-3-cycloheptylpropionylamido, N-ethyl-formylamino, N-ethyl-acetylamino, N-ethyl-propionylamino, N-ethyl-butanoylamino, N-ethyl-isobutanoylamino, N-ethyl-pentanoylamino, N-ethyl-3-methyl-butanoylamino, N-ethyl-hexanoylamino, N-ethyl-methoxycarbonylamino, N-ethyl-ethoxycarbonylamino, N-ethyl-n-propoxycarbonylamino, N-ethyl-isopropoxy-carbonylamino, N-ethyl-methanesulphonylamino, N-ethyl-ethanesulphonylamino, N-ethyl-n-propanesulphonylamino, N-ethyl-isopropanesulphonylamino, N-ethyl-n-butan-sulphonylamino, N-ethyl-n-pentansulphonylamino, N-ethyl-n-hexanesulphonylamino, N-ethyl-benzamido, N-ethyl-benzenesulphonylamido, N-ethyl-4-fluorobenzene-sulphonamido, N-ethyl-4-chlorobenzenesulphonamido, N-ethyl-4-bromobenzenesulphonamido, N-ethyl-4-methylbenzenesulphonamido, N-ethyl-4-methoxybenzenesulphonamido, N-ethyl-phenylmethanesulphonylamido, N-ethyl-2-phenylethanesulphonylamido, N-ethyl-3-phenylpropane-sulphonylamido, N-ethyl-naphthalen-1-yl-sulphonamido, N-ethyl-naphthalen-2-yl-sulphonylamido, N-ethyl-cyclopentylcarbonylamido, N-ethyl-cyclohexylcarbonylamido, N-ethyl-cycloheptylcarbonylamido, N-ethyl-phenylacetylamido, N-ethyl-3-phenyl-propionylamido, N-

ethyl-cyclopentylacetylamido, N-ethyl-3-cyclopentyl-propionylamido, N-ethyl-cyclohexylacetylamido, N-ethyl-3-cyclohexylpropionylamido, N-ethyl-cycloheptylacetylamido, N-ethyl-3-cycloheptylpropionylamido, N-n-propyl-formylamino, N-n-propyl-acetylamino, N-n-propyl-propionylamino, N-n-propyl-butanoylamino, N-n-propyl-isobutanoylamino, N-n-propyl-pentanoylamino, N-n-propyl-(3-methyl-butanoyl)amino, N-n-propyl-hexanoylamino, N-isopropyl-formylamino, N-isopropyl-acetylamino, N-isopropyl-propionylamino, N-isopropyl-butanoylamino, N-isopropyl-isobutanoylamino, N-isopropyl-pentanoylamino, N-isopropyl-(3-methyl-butanoyl)amino, N-isopropyl-hexanoylamino, N-n-butyl-formylamino, N-n-butyl-acetylamino, N-n-butyl-propionylamino, N-n-butyl-butanoylamino, N-n-butyl-isobutanoylamino, N-n-butyl-pentanoylamino, N-n-butyl-(3-methyl-butanoyl)amino, N-n-butyl-hexanoylamino, N-isobutyl-formylamino, N-isobutyl-acetylamino, N-isobutyl-propionylamino, N-isobutyl-butanoylamino, N-isobutyl-isobutanoylamino, N-isobutyl-pentanoylamino, N-n-pentyl-formylamino, N-n-pentyl-acetylamino, N-n-pentyl-propionylamino, N-n-pentyl-butanoylamino, N-n-pentyl-isobutanoylamino, N-n-pentyl-pentanoylamino, N-(1-methyl-butyl)-formylamino, N-(1-methyl-butyl)-acetylamino, N-(1-methyl-butyl)-propionylamino, N-(1-methyl-butyl)-butanoylamino, N-(1-methyl-butyl)-isobutanoylamino, N-(1-methyl-butyl)-pentanoylamino, N-(2-methyl-butyl)-formylamino, N-(2-methyl-butyl)-acetylamino, N-(2-methyl-butyl)-propionylamino, N-(2-methyl-butyl)-butanoylamino, N-(2-methyl-butyl)-isobutanoylamino, N-(2-methyl-butyl)-pentanoylamino, N-(3-methyl-butyl)-formylamino, N-(3-methyl-butyl)-acetylamino, N-(3-methyl-butyl)-propionylamino, N-(3-methyl-butyl)-butanoylamino, N-(3-methyl-butyl)-isobutanoylamino, N-(3-methyl-butyl)-pentanoylamino, N-n-hexyl-formylamino, N-n-hexyl-acetylamino, N-n-hexyl-propionylamino, N-n-hexyl-butanoylamino, N-n-hexyl-isobutanoylamino, N-n-hexyl-

pentanoylamino, N-n-propyl-cyclohexylcarbonylamino, N-n-propyl-cyclohexylacetylamino, N-n-propyl-3-(cyclohexyl)propionylamino, N-isopropyl-cyclohexylcarbonylamino, N-isopropyl-cyclohexylacetylamino, N-isopropyl-3-(cyclohexyl)-propionylamino, N-n-butyl-cyclohexylcarbonylamino, N-n-butyl-cyclohexylacetylamino, N-n-butyl-3-(cyclohexyl)-propionylamino, N-isobutyl-cyclohexylcarbonylamino, N-isobutyl-cyclohexylacetylamino, N-isobutyl-3-(cyclohexyl)propionylamino, N-n-pentyl-cyclohexylcarbonylamino, N-n-pentyl-cyclohexylacetylamino, N-n-pentyl-3-(cyclohexyl)propionylamino, N-n-hexyl-cyclohexylcarbonylamino, N-n-hexyl-cyclohexylacetylamino, N-n-hexyl-3-(cyclohexyl)propionylamino, phthalimino, 5-methoxy-phthalimino, 5,6-dimethoxy-phthalimino, 6-methoxy-phthalimino, homophthalimino, 4,4-dimethyl-homophthalimino, 7-methoxy-homophthalimino, 6,7-dimethoxy-homophthalimino, 7-methoxy-4,4-dimethyl-homophthalimino, 6,7-dimethoxy-4,4-dimethyl-homophthalimino, 1,2,3,6-tetrahydrophthalimino, hexahydrophthalimino, cis-hexahydrophthalimino, trans-hexahydrophthalimino, 1-oxo-isoindolin-2-yl, 3,4-dimethyl-phthalimino, 4,5-dimethyl-1,2,3,6-tetrahydrophthalimino, 4,5-dimethyl-hexahydrophthalimino, 4,5-dimethyl-1-oxo-isoindolin-2-yl, 3,4-dimethoxy-phthalimino, 4,5-dimethoxy-1,2,3,6-tetrahydrophthalimino, 4,5-dimethoxy-hexahydrophthalimino, 4,5-dimethoxy-1-oxo-isoindolin-2-yl, 2-carboxyphenylmethylamino, 2-carboxyphenylmethylene-carbonylamino, pyrrolidino, 2-methylpyrrolidino, 3-ethylpyrrolidino, 3-isopropylpyrrolidino, piperidino, 3-methylpiperidino, 4-methylpiperidino, 4-ethylpiperidino, 4-isopropylpiperidino, hexamethyleneimino, 3-methyl-hexamethyleneimino, 4-methylhexamethyleneimino, 3-ethylhexamethyleneimino, 4-isopropylhexamethyleneimino, 3,3-dimethyl-pyrrolidino, 3,4-dimethyl-pyrrolidino, 3,3-dimethyl-piperidino, 3,4-dimethyl-piperidino, 4,4-

dimethyl-piperidino, 3,3-dimethyl-hexamethyleneimino, 3,4-dimethyl-hexamethyleneimino, 4,4-dimethyl-hexamethyleneimino, 3,5-dimethyl-hexamethyleneimino, 3,3-tetramethylene-pyrrolidino, 3,3-pentamethylene-pyrrolidino, 3,3-tetramethylene-piperidino, 3,3-pentamethylene-piperidino, 4,4-tetramethylene-piperidino, 4,4-pentamethylene-piperidino, 3,3-tetramethylene-hexamethyleneimino, 3,3-pentamethylene-hexamethyleneimino, 4,4-tetramethylene-hexamethyleneimino, 4,4-pentamethylene-hexamethyleneimino, 2-oxo-pyrrolidino, 2-oxo-piperidino, 2-oxo-hexamethyleneimino, propanesultam-1-yl, butanesultam-1-yl, pentanesultam-1-yl, endo-bicyclo[2.2.2]oct-5-ene-2,3-dicarboxylic acid imino, methyl-5-norbornene-2,3-dicarboxylic acid imino, 3,6-endooxo-1,2,3,6-tetrahydrophthalimino, 5-norbornen-endo-2,3-dicarboxylic acid imino, glutarimino, 3,3-tetramethylene-glutarimino, 3,3-pentamethylene-glutarimino, 2,2-dimethyl-glutarimino, 3-methyl-glutarimino, 3,3-dimethyl-glutarimino, 3-ethyl-glutarimino, 3-ethyl-3-methyl-glutarimino, 1,3-cyclopentanedicarbonylimino, 2,4-dimethyl-glutarimino, 2,4-di-n-propyl-glutarimino, glutaramino, 3,3-tetramethylene-glutaramino, 3,3-pentamethylene-glutaramino, 2,2-dimethyl-glutaramino, 3-methyl-glutaramino, 3,3-dimethyl-glutaramino, 3-ethyl-glutaramino, 3-ethyl-3-methyl-glutaramino, 1,3-cyclopentanedicarbonylamino, 2,4-dimethyl-glutaramino, 2,4-di-n-propyl-glutaramino, maleic acid amido, maleic acid imido, 2-methyl-maleic acid amido, 3-methyl-maleic acid amido, 2-methyl-maleic acid imido, 2-phenyl-maleic acid amido, 3-phenyl-maleic acid amido, 2-phenyl-maleic acid imido, 2,3-dimethyl-maleic acid amido, 3-methyl-2-phenyl-maleic acid amido, 2-methyl-3-phenyl-maleic acid amido, 2-methyl-3-phenyl-maleic acid imido, 2,3-diphenyl-maleic acid amido, pyrrolidin-2-yl, pyrrolidin-2-on-5-yl, piperidin-2-yl, piperidin-2-on-1-yl, piperidin-2-on-6-yl,



quinolin-2-yl, isoquinolin-1-yl, isoquinolin-3-yl,
pyridin-2-yl, 4-methylimidazol-2-yl, 1-methylimidazol-4-
yl, 1-methylimidazol-5-yl, 1-n-hexylimidazol-4-yl, 1-n-
hexylimidazol-5-yl, 1-benzylimidazol-4-yl, 1-
benzylimidazol-5-yl, 1,2-dimethylimidazol-4-yl, 1,2-
dimethylimidazol-5-yl, 1-n-pentyl-2-methyl-imidazol-4-
yl, 1-n-pentyl-2-methyl-imidazol-5-yl, 1-n-butyl-2-
methyl-imidazol-4-yl, 1-n-butyl-2-methyl-imidazol-5-yl,
1-benzyl-2-methyl-imidazol-4-yl, 1-benzyl-2-methyl-
imidazol-5-yl, benzimidazol-2-yl, 1-methylbenzimidazol-
2-yl, 1-ethylbenzimidazol-2-yl, 1-n-propylbenzimidazol-
2-yl, 1-isopropylbenzimidazol-2-yl, 1-n-
butylbenzimidazol-2-yl, 1-isobutylbenzimidazol-2-yl, 1-
n-pentylbenzimidazol-2-yl, 1-n-hexylbenzimidazol-2-yl,
1-cyclopropyl-benzimidazol-2-yl, 1-
cyclobutylbenzimidazol-2-yl, 1-cyclopentylbenzimidazol-
2-yl, 1-cyclohexylbenzimidazol-2-yl, 5-nitro-
benzimidazol-2-yl, 5-amino-benzimidazol-2-yl, 5-
acetamido-benzimidazol-2-yl, 5-methyl-benzimidazol-2-yl,
5-methoxy-benzimidazol-2-yl, 5-ethoxy-benzimidazol-2-yl,
1-methyl-5-methoxy-benzimidazol-2-yl, 1,5-dimethyl-
benzimidazol-2-yl, 1,6-dimethyl-benzimidazol-2-yl, 1,4-
dimethyl-benzimidazol-2-yl, 5,6-dimethyl-benzimidazol-2-
yl, 1,5,6-trimethyl-benzimidazol-2-yl, 5-chloro-
benzimidazol-2-yl, 5-chloro-1-methyl-benzimidazol-2-yl,
6-chloro-1-methyl-benzimidazol-2-yl, 5,6-dichloro-1-
methyl-benzimidazol-2-yl, 5-dimethylamino-benzimidazol-
2-yl, 5-dimethylamino-1-ethyl-benzimidazol-2-yl, 5,6-
dimethoxy-1-methyl-benzimidazol-2-yl, 5,6-dimethoxy-1-
ethyl-benzimidazol-2-yl, 5-fluoro-1-methyl-benzimidazol-
2-yl, 6-fluoro-1-methyl-benzimidazol-2-yl, 5-
trifluoromethyl-benzimidazol-2-yl, 5-trifluoromethyl-1-
methyl-benzimidazol-2-yl, 4-cyano-1-methyl-benzimidazol-
2-yl, 5-carboxy-1-methyl-benzimidazol-2-yl, 5-
aminocarbonyl-benzimidazol-2-yl, 5-aminocarbonyl-1-
methyl-benzimidazol-2-yl, 5-dimethylaminosulphonyl-1-
methyl-benzimidazol-2-yl, 5-methoxycarbonyl-1-methyl-

benzimidazol-2-yl, 5-methylaminocarbonyl-1-methyl-
 benzimidazol-2-yl, 5-dimethylaminocarbonyl-1-methyl-
 benzimidazol-2-yl, 4,6-difluoro-1-methyl-benzimidazol-2-
 yl, 5-acetyl-1-methyl-benzimidazol-2-yl, 5,6-dihydroxy-
 1-methyl-benzimidazol-2-yl, imidazo[1,2-a]pyridin-2-yl,
 5-methyl-imidazo[1,2-a]pyridin-2-yl, 6-methyl-
 imidazo[1,2-a]-pyridin-2-yl, 7-methyl-imidazo[1,2-a]-
 pyridin-2-yl, 8-methyl-imidazo[1,2-a]pyridin-2-yl, 5,7-
 dimethyl-imidazo[1,2-a]pyridin-2-yl, 6-aminocarbonyl-
 imidazo[1,2-a]pyridin-2-yl, 6-chloro-imidazo[1,2-a]-
 pyridin-2-yl, 6-bromo-imidazo[1,2-a]pyridin-2-yl,
 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl,
 imidazo[1,2-a]pyrimidin-2-yl, 5,7-dimethyl-
 imidazo[1,2-a]pyrimidin-2-yl, imidazo[4,5-b]pyridin-2-
 yl, 1-methyl-imidazo[4,5-b]pyridin-2-yl, 1-n-hexyl-
 imidazo[4,5-b]pyridin-2-yl, 1-cyclopropyl-
 imidazo[4,5-b]pyridin-2-yl, 1-cyclohexyl-imidazo[4,5-b]-
 pyridin-2-yl, 4-methyl-imidazo[4,5-b]pyridin-2-yl, 6-
 methyl-imidazo[4,5-b]pyridin-2-yl, 1,4-dimethyl-
 imidazo[4,5-b]pyridin-2-yl, 1,6-dimethyl-imidazo[4,5-b]-
 pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, 1-methyl-
 imidazo[4,5-c]pyridin-2-yl, 1-n-hexyl-imidazo[4,5-c]-
 pyridin-2-yl, 1-cyclopropyl-imidazo[4,5-c]pyridin-2-yl,
 1-cyclohexyl-imidazo[4,5-c]pyridin-2-yl, imidazo[2,1-b]-
 thiazol-6-yl, 3-methyl-imidazo[2,1-b]thiazol-6-yl, 2-
 phenyl-imidazo[2,1-b]thiazol-6-yl, 3-phenyl-
 imidazo[2,1-b]thiazol-6-yl, 2,3-dimethyl-imidazo[2,1-b]-
 thiazol-6-yl, 2,3-trimethylene-imidazo[2,1-b]thiazol-6-
 yl, 2,3-tetramethylene-imidazo[2,1-b]thiazol-6-yl,
 imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-
 yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[4,5-c]pyridin-
 2-yl, purin-8-yl, imidazo[4,5-b]pyrazin-2-yl,
 imidazo[4,5-c]pyridazin-2-yl, imidazo[4,5-d]pyridazin-2-
 yl, imidazolidin-2,4-dion-3-yl, 5-methyl-imidazolidin-
 2,4-dion-3-yl, 5-ethyl-imidazolidin-2,4-dion-3-yl, 5-n-
 propyl-imidazolidin-2,4-dion-3-yl, 5-benzyl-
 imidazolidin-2,4-dion-3-yl, 5-(2-phenylethyl)-



imidazolidin-2,4-dion-3-yl, 5-(3-phenylpropyl)-
imidazolidin-2,4-dion-3-yl, 5,5-tetramethylene-
imidazolidin-2,4-dion-3-yl, 5,5-pentamethylene-
imidazolidin-2,4-dion-3-yl, 5,5-hexamethylene-
imidazolidin-2,4-dion-3-yl, 1-methyl-imidazolidin-2,4-
dion-3-yl, 1-benzyl-imidazolin-2,4-dion-3-yl, 4,5-
dihydro-2H-pyridazin-3-on-6-yl, 2-methyl-4,5-dihydro-2H-
pyridazin-3-on-6-yl, 2-ethyl-4,5-dihydro-2H-pyridazin-3-
on-6-yl, 2-n-propyl-4,5-dihydro-2H-pyridazin-3-on-6-yl,
2-isopropyl-4,5-dihydro-2H-pyridazin-3-on-6-yl, 2-
benzyl-4,5-dihydro-2H-pyridazin-3-on-6-yl, 2-(2-
phenylethyl)-4,5-dihydro-2H-pyridazin-3-on-6-yl, 2-(3-
phenylpropyl)-4,5-dihydro-2H-pyridazin-3-on-6-yl, 4-
methyl-4,5-dihydro-2H-pyridazin-3-on-6-yl, 5-methyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 4,4-dimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 5,5-dimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 4,5-dimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 2,4-dimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 2,5-dimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 2,4,5-trimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 2,4,4-trimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 2,5,5-trimethyl-4,5-
dihydro-2H-pyridazin-3-on-6-yl, 2H-pyridazin-3-on-6-yl,
2-methyl-pyridazin-3-on-6-yl, 2-ethyl-pyridazin-3-on-6-
yl, 2-n-propyl-pyridazin-3-on-6-yl, 2-isopropyl-
pyridazin-3-on-6-yl, 2-benzyl-pyridazin-3-on-6-yl, 2-(2-
phenylethyl)-pyridazin-3-on-6-yl, 2-(3-phenylpropyl)-
pyridazin-3-on-6-yl, 4-methyl-pyridazin-3-on-6-yl, 5-
methyl-pyridazin-3-on-6-yl, 4,5-dimethyl-pyridazin-3-on-
6-yl, 2,4-dimethyl-pyridazin-3-on-6-yl, 2,5-dimethyl-
pyridazin-3-on-6-yl, 2,4,5-trimethyl-pyridazin-3-on-6-
yl, aminocarbonylamino, methylaminocarbonylamino,
dimethylaminocarbonylamino, N-methylaminocarbonyl-
methylamino, N-(dimethylaminocarbonyl)-methylamino, W-
dimethylaminocarbonyl-ethylamino, N-dimethylamino-
carbonyl-isopropylamino, N-(dimethylaminocarbonyl)-n-
pentylamino, N-methylaminocarbonyl-ethylamino, N-

methylaminocarbonyl-n-pentylamino, N-methylamino-carbonyl-n-hexylamino, N-methylaminocarbonyl-n-octylamino, N-methylaminocarbonyl-cyclohexylamino, ethylaminocarbonylamino, N-ethylaminocarbonyl-methylamino, N-ethylaminocarbonyl-ethylamino, N-ethylaminocarbonyl-n-hexylamino, N-ethylaminocarbonyl-n-heptylamino, N-ethylaminocarbonyl-cyclohexylamino, diethylaminocarbonylamino, N-(diethylaminocarbonyl)-methylamino, N-(diethylaminocarbonyl)-ethylamino, N-(diethylaminocarbonyl)-n-butylamino, N-(diethylaminocarbonyl)-n-hexylamino, N-(diethylaminocarbonyl)-n-octylamino, isopropylaminocarbonylamino, N-isopropylaminocarbonyl-methylamino, n-butylaminocarbonylamino, N-(n-butylaminocarbonyl)-methylamino, N-(n-butylaminocarbonyl)-ethylamino, N-(n-butylaminocarbonyl)-isopropylamino, N-(n-butylaminocarbonyl)-n-butylamino, N-(n-butylaminocarbonyl)-n-hexylamino, N-(n-butylaminocarbonyl)-cyclohexylamino, N-(di-(n-butyl)-aminocarbonyl)-amino, N-(di-(n-butyl)-aminocarbonyl)-methylamino, N-(di-(n-butyl)-aminocarbonyl)-ethylamino, N-(di-(n-butyl)-aminocarbonyl)-n-butylamino, N-(di-(n-butyl)-aminocarbonyl)-n-hexylamino, N-(n-pentylaminocarbonyl)-methylamino, N-(n-pentylaminocarbonyl)-ethylamino, N-(n-hexylaminocarbonyl)-ethylamino, n-hexylaminocarbonylamino, n-heptylaminocarbonylamino, n-octylaminocarbonylamino, N-(n-hexylaminocarbonyl)-n-butylamino, N-(n-hexylaminocarbonyl)-n-pentylamino, N-(n-hexylaminocarbonyl)-n-hexylamino, N-(n-hexylaminocarbonyl)-cyclohexylamino, di-(n-hexyl)-aminocarbonylamino, N-(di-(n-hexyl)-aminocarbonyl)-methylamino, N-((n-hexyl)-methylaminocarbonyl)-amino, cyclohexylaminocarbonylamino, N-cyclohexylaminocarbonyl-methylamino, N-cyclohexylaminocarbonyl-ethylamino, N-cyclohexylaminocarbonyl-n-butylamino, N-cyclohexylaminocarbonyl-isobutylamino, N-cyclohexylaminocarbonyl-n-pentylamino, N-cyclohexylaminocarbonyl-n-hexylamino, N-cyclohexylaminocarbonyl-cyclohexylamino, N-(ethyl-

cyclohexylaminocarbonyl)-methylamino, N-(propyl-cyclohexylaminocarbonyl)-methylamino, N-(n-butyl-cyclohexylaminocarbonyl)-methylamino, allylaminocarbonylamino, **benzylaminocarbonylamino**, N-benzylaminocarbonyl-isobutylamino, phenylaminocarbonylamino, pyrrolidinocarbonylamino, pyrrolidinocarbonyl-methylamino, piperidinocarbonylamino, hexamethylene-**iminocarbonylamino**, morpholinocarbonylamino, 3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-methyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-ethyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-n-propyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-isopropyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-n-butyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-isobutyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-n-pentyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-n-hexyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-cyclopentyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-cyclohexyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-cycloheptyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3-benzyl-3,4,5,6-tetrahydro-2-pyrimidon-1-yl, 3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl, 3-methyl-3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl, 3-ethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl, 3-n-propyl-3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl, 3-isopropyl-3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl, 3-benzyl-3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl, 3-(2-phenylethyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl or 3-(3-phenylpropyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidon-1-yl group; and

R₃ may represent a hydrogen atom, a methyl, **ethyl**, n-propyl, isopropyl, n-butyl, **isobutyl**, tert.butyl, n-pentyl, 1-methyl-butyl, 2-methyl-butyl, 4-methyl-butyl, **cyclopropyl**, **cyclobutyl**, cyclopentyl, **methoxy**, **ethoxy**, **n-propoxy**, **isopropoxy**, n-butoxy, methylmercapto, ethylmercapto, **n-propylmercapto**, isopropylmercapto or n-butylmercapto group.

Preferred compounds according to the invention include compounds of formula I

wherein

R_1 in the 4-position represents a fluorine, chlorine or bromine atom, a C_{1-3} -alkyl group, or a cycloalkyl, fluoromethyl, difluoromethyl or trifluoromethyl group, and

R_2 represents a C_{3-5} -alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R_2 represents a C_{2-5} -alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

an acylamino group optionally substituted at the nitrogen atom by a C_{1-4} -alkyl group, wherein the acyl group is a C_{2-7} -alkanoyl group, a C_{2-4} (alkoxycarbonyl) group, a C_{1-3} -alkylsulphonyl group or a benzenesulphonyl group,

a phthalimino or homophthalimino group, wherein a carbonyl group in a phthalimino group may be replaced by a methylene group and a methylene in a homophthalimino group may be substituted by one or two alkyl groups,

a 5-, 6- or 7-membered alkyleneimino or alkenyleneimino group, optionally substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group, wherein a methylene group may be replaced by a carbonyl or sulphonyl group,

a glutaric acid imino group wherein the n -prbpylene group may be perfluorinated, or may be substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group,

a maleic acid imido group optionally mono- or disubstituted by an alkyl or phenyl group, whilst the substituents may be identical or different,

an amidino group optionally substituted by one or two C_{1-4} alkyl groups,

a benzimidazol-2-yl group optionally substituted in the 1-position by C_{1-6} -alkyl or a cycloalkyl group and optionally substituted in the phenyl nucleus by a fluorine atom or by a methyl or trifluoromethyl group,

or R_2 represents an imidazo[2,1-b]thiazol-6-yl, imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[4,5-c]pyridin-2-yl, purin-8-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl or imidazo[4,5-d]pyridazin-2-yl group, or a carbon attached pyrrolidine, piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group,

a carbon attached imidazolyl group optionally substituted in the 1-position by a C_{1-3} -alkyl group or by a benzyl group, and which may also be substituted in the carbon skeleton by a C_{1-3} -alkyl group,

an imidazolidindione group optionally substituted by an alkyl, phenylalkyl, tetramethylene, pentamethylene or hexamethylene group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which

may be substituted in the 2-position by a methyl or benzyl group,

an $R_7-NR_6-CO-NR_5-$ group

(wherein

R_5 represents a hydrogen atom, a C_{1-3} -alkyl group, a cyclohexyl or benzyl group,

R_6 represents a hydrogen atom, a C_{1-4} -alkyl group, an allyl, cyclohexyl, benzyl or phenyl group,

R_7 represents a hydrogen atom or a C_{1-3} -alkyl group or

R_6 and R_7 together with the nitrogen atom between them represent an unbranched C_{4-6} -alkyleneimino group or a morpholino group or

R_5 and R_6 together represent a C_{2-3} -alkylene group);

or R_1 represents a hydrogen atom or in the 5-, 6- or 7-position R_1 represents a fluorine, chlorine or bromine atom or a C_{1-4} -alkyl or a trifluoromethyl group, and

R_2 represents a benzimidazol-2-yl group optionally substituted in the 1-position by a C_{1-6} -alkyl group or by a cycloalkyl group, and optionally substituted in the phenyl nucleus by a fluorine atom or by a methyl or trifluoromethyl group,

or R_2 represents an imidazo[2,1-b]thiazol-6-yl, imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[4,5-c]-

pyridin-2-yl, purin-8-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl or imidazo[4,5-d]-pyridazin-2-yl group, or a carbon attached pyrrolidine, piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine ring via 2 adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group, or a carbon attached imidazolyl group optionally substituted in the 1-position by a C_{1-3} alkyl group or by a benzyl group which may also be substituted in the carbon skeleton by a C_{1-3} alkyl group, with the proviso that where

- (i) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy or 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where
- (ii) R_1 represents a hydrogen atom, R_3 represents a methyl, ethyl or n-butyl group and R_4 represents a 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position, and where
- (iii) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a benzimidazol-2-yl group in the 6-position, and where
- (iv) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a fluorine atom, by a methyl or trifluoromethyl group or in the 6-position by a methyl group, or a 1-n-butyl-benzimidazol-2-yl



group in the 6-position, and where

(v) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-n-butyl-5-trifluoromethyl-benzimidazol-2-yl or 1-n-hexyl-5-methyl-benzimidazol-2-yl group in the 6-position, and where

(vi) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position;

R_3 represents a C_{1-5} -alkyl group or a C_{3-5} -cycloalkyl group; and

R_4 represents a carboxy or 1H-tetrazolyl group;

wherein, unless otherwise specified, each alkanoyl, alkyl or alkoxy moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms;

and the isomers, isomer mixtures and addition salts thereof.

Particularly preferred compounds according to the invention include those of formula I

wherein

R_1 in the 4-position represents a chlorine atom, or a C_{1-3} -alkyl or a trifluoromethyl group, and



R_2 represents a $C_{3,5}$ -alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R_2 represents a $C_{2,5}$ -alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

a $C_{2,5}$ (alkanoyl)amino or N-benzenesulphonyl-methylamino group,

a phthalimino or homophthalimino group, wherein a carbonyl group in a phthalimino group may be replaced by a methylene group,

a 5-, 6- or 7-membered alkyleneimino group wherein a methylene group is replaced by a carbonyl or sulphonyl group,

a glutaric acid imino group wherein the n-propylene group may be substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group,

a maleic acid imido group optionally mono- or disubstituted by an alkyl or phenyl group, whilst the substituents may be identical or different,

a benzimidazol-2-yl group optionally substituted in the 1-position by a $C_{1,6}$ -alkyl group or by a cycloalkyl group, and optionally substituted in the phenyl nucleus by a fluorine atom or by a methyl or trifluoromethyl group,

or R_2 represents an imidazo[2,1-b]thiazol-6-yl, imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[4,5-c]pyridin-2-yl, purin-8-yl,

imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl or imidazo[4,5-d]pyridazin-2-yl group, or a carbon attached pyrrolidine, piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group,

or R_2 represents an imidazol-4-yl group substituted in the 1-position by a C_{1-3} alkyl group or by a benzyl group which may also be substituted in the carbon skeleton by a C_{1-3} alkyl group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by a methyl or benzyl group,

an $R_7-NR_6-CO-NR_5-$ group

(wherein

R_5 represents a hydrogen atom or a C_{1-6} -alkyl, cyclohexyl or benzyl group,

R_6 represents a hydrogen atom, a C_{1-6} -alkyl group or an allyl, cyclohexyl, benzyl or phenyl group,

R_7 represents a hydrogen atom or a C_{1-6} -alkyl group or

R_6 and R_7 together with the nitrogen atom between them represent an unbranched C_{4-6} -alkyleneimino group or a morpholino group or

R_5 and R_6 together represent a C_{2-3} -alkylene group);

or R_1 represents a hydrogen atom or in the 5-, 6- or 7-position R_1 represents a C_{1-4} -alkyl group or a

trifluoromethyl group, and

R_2 represents a benzimidazol-2-yl group optionally substituted in the **1-position** by a **C₁₋₆-alkyl** group or by a cycloalkyl group and optionally substituted in the phenyl nucleus **by** a fluorine atom or by a methyl or trifluoromethyl group,

or R_2 represents an **imidazo[2,1-b]thiazol-6-yl**, **imidazo[1,2-a]pyridin-2-yl**, **5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl**, **imidazo[1,2-a]pyrimidin-2-yl**, **imidazo[4,5-b]pyridin-2-yl**, **imidazo[4,5-c]pyridin-2-yl**, **imidazo[1,2-c]pyrimidin-2-yl**, **imidazo[1,2-a]pyrazin-2-yl**, **imidazo[1,2-b]-pyridazin-2-yl**, **imidazo[4,5-c]-pyridin-2-yl**, **purin-8-yl**, **imidazo[4,5-b]pyrazin-2-yl**, **imidazo[4,5-c]pyridazin-2-yl** or **imidazo[4,5-d]pyridazin-2-yl** group, or a carbon attached pyrrolidine, piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine ring via two **adjacent** carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may **be** replaced by a **carbonyl** group, or an imidazol-4-yl group substituted in the **1-position** by a **C₁₋₃** alkyl group or by a **benzyl**-group which may also be substituted in the carbon **skeleton** by a **C₁₋₃** alkyl group, with the proviso that where

(i) R_1 represents a hydrogen atom, R_3 represents an n-propyl **group** and R_4 represents a carboxy or **1H-tetrazolyl** group, then R_2 cannot **represent** a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where

(ii) R_1 represents a hydrogen atom, R_3 represents a methyl, ethyl or n-butyl group and R_4 represents a **1H-tetrazolyl** group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl **group in the 6-position**, and where



- (iii) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a benzimidazol-2-yl group in the **6-position**, and where
- (iv) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the **5-position** by a **fluorine** atom, by a methyl or trifluoromethyl group or in the 6-position by a methyl group, or a 1-n-butyl-benzimidazol-2-yl group in the 6-position, and where
- (v) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-n-butyl-5-trifluoromethyl-benzimidazol-2-yl or **1-n-hexyl-5-methyl-benzimidazol-2-yl** group in the 6-position, and where
- (vi) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a **carboxy** group, then R_2 cannot represent a **1-methylbenzimidazol-2-yl** group in the G-position;

R_3 represents a **C₁₋₅-alkyl** group or a **C₃₋₅-cycloalkyl** group; and

R_4 represents a **carboxy** or **1H-tetrazolyl** group;

wherein, unless otherwise specified, each alkanoyl,



alkyl or alkoxy moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms;

and the isomers, isomer mixtures and addition salts thereof.

Especially preferred compounds according to the invention include those of formula I

wherein

R₁ in the 4-position represents a chlorine atom or a methyl group, and

R₂ represents a C₃₋₅-alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R₂ represents a C₂₋₅-alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

a C₂₋₅(alkanoyl)amino group or N-benzenesulphonyl-methylamino group,

a phthalimino or homophthalimino group, wherein a carbonyl group in a phthalimino group may be replaced by a methylene group,

a 5-, 6- or 7-membered alkyleneimino group, wherein a methylene group is replaced by a carbonyl or sulphonyl group,

a maleic acid imido group optionally mono- or disubstituted by an alkyl or phenyl group, whilst the substituents may be identical or different,

a benzimidazol-2-yl group optionally substituted in the 1-position by a C_n-alkyl group and optionally

substituted in the phenyl nucleus by a fluorine atom,

or R_2 represents an imidazo[1,2-a]-pyridin-2-yl group, 5,6,7,8-tetrahydro-imidazo[1,2-a]-pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl or imidazo[2,1-b]thiazol-6-yl group,

an imidazol-4-yl group substituted in the 1-position by a C_{1-3} alkyl group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by a methyl or benzyl group; or

R_1 represents a hydrogen atom or in the 5-, 6- or 7-position R_3 represents a methyl group, and

R_2 represents a benzimidazol-2-yl group optionally substituted in the 1-position by a C_{1-3} -alkyl group, and optionally substituted in the phenyl nucleus by a fluorine atom,

or R_2 represents an imidazo[1,2-a]pyridin-2-yl group, or an imidazol-4-yl group substituted in the 1-position by a C_{1-3} alkyl group, with the proviso that where

(i) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy or 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where

(ii) R_1 represents a hydrogen atom, R_3 represents a methyl, ethyl or n-butyl group and R_4 represents a 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position, and where



(iii) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a benzimidazol-2-yl group in the 6-position, and where

(iv) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a fluorine atom, and where

(v) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position;

R_3 represents a C_{1-5} -alkyl group or a C_{3-5} -cycloalkyl group; and

R_4 represents a carboxy or 1H-tetrazolyl group;

wherein, unless otherwise specified, each alkanoyl,

-



alkyl or alkoxy moiety contains 1 to 3 carbon atoms **and** each cycloalkyl moiety contains 3 to 7 carbon atoms;

and the isomers, isomer **mixtures** and addition salts thereof,

Even more especially preferred compounds according to the invention include those of formula I

(wherein

R₁ in the 4-position represents a **chlorine** atom or a methyl group, **and**

R₂ represents a **benzimidazol-2-yl** group optionally substituted in the **1-position** by a C₁₋₃-**alkyl** group and optionally substituted in the **phenyl** nucleus by a fluorine atom, or

R₂ represents an **imidazo[1,2-a]pyridin-2-yl**, 5,6,7,8-tetrahydro-imidazo[1,2-a]-**pyridin-2-yl**, imidazo[1,2-a]-pyrimidin-2-yl or imidazo(2,1-b)thiazol-6-yl group, and

R₃ represents a C₁₋₅-**alkyl** group or a C₃₋₅-**cycloalkyl** group, **and**

R₄ represents a **carboxy** or **1H-tetrazolyl** group)

and the **isomers**, isomer **mixtures** and addition salts thereof.

The present invention **particularly encompasses** the following compounds:

4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;



4' - [[2-n-propyl-4-methyl-6- (1-methylbenzimidazol-2-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-propyl-4-methyl-6- (1-oxo-isoindolin-2-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-propyl-4-methyl-6- (butanesultam-1-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-butyl-6- (2,3-dimethylmaleic acid imino) -4-
methylbenzimidazol-1-yl] -methyl] -biphenyl-2-carboxylic
acid;

4' - [[2-n-butyl-6- (isopropylcarbonylamino) -4-methyl-
benzimidazol-1-yl] -methyl] -biphenyl-2-carboxylic acid;

4' - [[2-n-butyl-4-methyl-6- (morpholinocarbonylamino) -
benzimidazol-1-yl] -methyl] -biphenyl-2-carboxylic acid;

4' - [[2-n-butyl-6- (cyclohexylaminocarbonylamino) -4-
methyl-benzimidazol-1-yl] -methyl] -biphenyl-2-carboxylic
acid;



4'-[[2-cyclopropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4'-[[2-n-propyl-4-methyl-6-(1-methyl-5-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4'-[[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-propyl-4-methyl-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4'-[[2-n-propyl-4-methyl-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-propyl-4-chloro-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4'-[[2-ethyl-4-methyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-butyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-propyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-



biphenyl;

4'-[[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4'-[[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-propyl-4-methyl-6-(1-methyl-6-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid; and

4'-[[2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

and the isomers, isomer mixtures and addition salts thereof.

Especially preferred compounds according to the invention include:

4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;


4'-[[2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

and the isomers, isomer mixtures and addition salts thereof.



Viewed from another aspect, the invention provides a process for preparing compounds of formula I and salts thereof which process comprises at least one of the following steps:

a) cyclising compound of formula II




(wherein

R₁ and R₂ are as defined hereinbefore,


one of the groups X₁ or Y₁ represents a group of formula II(a)





II(a)

and the other group X_1 or Y_1 , represents a group of the formula II(b)



II(b)

(wherein


R_8 represents a hydrogen atom or an R_3CO- group, R_3 and R_4 are as defined hereinbefore,

Z_1 and Z_2 , which may be identical or different, represent optionally substituted amino groups or hydroxy or mercapto groups optionally substituted by lower (e.g. C_{1-6}) alkyl groups or

Z_1 and Z_2 together represent an oxygen or sulphur atom, an optionally C_{1-3} -alkyl substituted imino group, an alkylenedioxy or alkylenedithio group, each having 2 or 3 carbon atoms))

and any corresponding N-oxide thus obtained is reduced;

b) reacting a compound of formula III




(III)



(wherein

R_1 to R_3 are as defined hereinbefore)

with a biphenyl compound of formula IV




(wherein

R_4 is as defined hereinbefore, and

Z_3 represents a nucleophilic leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom, or a substituted sulphonyloxy group, e.g. a methanesulphonyloxy, phenylsulphonyloxy or p-toluenesulphonyloxy group);

c) (to prepare compounds of formula I wherein R_4 represents a carboxy group) converting a compound of formula V




(wherein

R_1 to R_3 are as defined hereinbefore, and

R_4' represents a group which may be converted into a carboxy group by hydrolysis, thermolysis or hydrogenolysis) into a corresponding carboxy compound;


d) (to prepare compounds of formula I wherein R_4 represents a 1H-tetrazolyl group) cleaving a protecting group from a compound of formula VI



(wherein

R_1 , R_2 and R_3 are as defined hereinbefore, and R_4'' represents a 1H-tetrazolyl group protected in the 1- or 3-position by a protecting group);


e) (to prepare compounds of formula I wherein R_4 represents a 1H-tetrazolyl group) reacting a compound of formula VII



(wherein

R_1 to R_3 are as defined hereinbefore) with hydrazoic acid or a salt thereof;

f) (to prepare compounds of formula I wherein R_2 represents one of the imidazo[1,2-a]-pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-C]-pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]pyridazin-2-yl or imidazo[2,1-b]thiazol-6-yl groups) reacting a compound of formula VIII




(wherein

one of the groups A, B, C or D represents a methine group or a nitrogen atom and the remaining groups A, B, C or D represent methine groups, or

A and B each represent methine and the -C=D- moiety represents a sulphur atom,

R₉ represents a hydrogen, fluorine, chlorine or bromine atom or an alkyl, alkoxy, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkanoyl, aminosulphonyl, alkylaminosulphonyl or dialkylamino-sulphonyl group, and


R₁₀ represents a hydrogen, fluorine or chlorine atom or a methyl, methoxy or hydroxy group; or R₉ and R₁₀ attached at adjacent ring positions together represent a propylene or n-butylene group) with a compound of formula IX



(wherein

R₁, R₃ and R₄ are as defined hereinbefore and Z₄ represents a nucleophilic leaving group such as a halogen atom, e.g. a chlorine or bromine atom);

g) (to prepare compounds of formula I wherein R_2 represents one of the benzimidazol-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl, imidazo[4,5-d]pyridazin-2-yl or purin-8-yl groups) cyclising a compound of formula X




(wherein none, one or two of the groups A_1 , B_1 , C_1 or D_1 represents a nitrogen atom and the remaining groups A_1 , B_1 , C_1 or D_1 represent methine groups;

R_{11} represents a hydrogen, fluorine, chlorine or bromine atom or an alkyl, alkoxy, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkanoyl, aminosulphonyl, alkylaminosulphonyl or dialkylamino-sulphonyl group; and

R_{12} represents a hydrogen, fluorine or chlorine atom or a methyl, methoxy or hydroxy group;

one of the groups X_2 or Y_2 represents an R_{13} -NH- group and the other X_2 or Y_2 group represents a group of formula $X(a)$



X(a)

(wherein


R₁, R₃ and R₄ are as defined hereinbefore;

one of the groups R₁₃ or R₁₄ represents a hydrogen atom and the other R₁₃ or R₁₄ group represents a hydrogen atom, a C₁₋₆-alkyl group or a cycloalkyl group, Z₅ and Z₆, which may be identical or different, represent optionally substituted amino groups or hydroxy or mercapto groups optionally substituted by lower (e.g. C₁₋₆) alkyl groups or

Z₅ and Z₆ together represent an oxygen or sulphur atom, an optionally C₁₋₃-alkyl substituted imino group, an alkylenedioxy or alkylenedithio group each having 2 or 3 carbon atoms))

and reducing any corresponding N-oxide thus obtained, and optionally hydrolysing the resulting product;

h) (to prepare compounds of formula I wherein R₂ represents a dihydro-pyridazin-3-one or pyridazin-3-one group which may be substituted in the 2-position by a C₁₋₃-alkyl group optionally substituted by a phenyl group, or in the carbon structure by one or two alkyl groups each having 1 to 3 carbon atoms) reacting a carboxylic acid of formula XII



(wherein

R_1 , R_3 and R_4 are as defined hereinbefore; and E represents an ethylene or ethenylene group optionally substituted by one or two C_{1-3} alkyl groups) or a reactive acid derivative thereof, such as an ester, amide or halide, with a hydrazine of formula XIII



(wherein

R_{15} represents a hydrogen atom or a C_{1-3} -alkyl group optionally substituted by a phenyl group);

- i) performing the reaction of any one of steps (a) to (h) using a starting material wherein a reactive group is protected by a protecting group and subsequently removing any protecting group used;
- j) resolving an isomer mixture into the separate component isomers;
- k) converting a compound of formula I into an addition salt thereof or converting a salt of a compound of formula I into the compound.

The cyclisation of reaction step (a) is conveniently carried out in a solvent or mixture of solvents such as ethanol, isopropanol, glacial acetic acid, benzene, chlorobenzene, toluene, xylene, glycol, glycoimonomethylether, diethyleneglycol-dimethylether,

sulpholane, dimethylformamide, tetraline or in an excess of the acylating agent used to prepare the compound of formula II, e.g. in the corresponding nitrile, anhydride, acid halide, ester or amide, e.g. at temperatures between 0 and 250°C, but preferably at the boiling temperature of the reaction mixture, optionally in the presence of a condensing agent such as phosphorusoxychloride, thionylchloride, sulphurylchloride, sulphuric acid, p-toluenesulphonic acid, methanesulphonic acid, hydrochloric acid, phosphoric acid, polyphosphoric acid, acetic anhydride or optionally in the presence of a base such as potassium ethoxide or potassium tert.-butoxide. However, cyclisation may also be carried out without a solvent and/or condensing agent.

However, it is particularly advantageous to carry out the reaction of step (a) by preparing a compound of formula 11 in the reaction mixture by reducing a corresponding o-nitro-amino compound, optionally in the presence of a carboxylic acid of formula R_3COOH , or by acylation of a corresponding o-diamino compound. When the reduction of the nitro group is broken off at the hydroxylamine stage, the N-oxide of a compound of formula I is obtained in the subsequent cyclisation, The resulting N-oxide is then converted by reduction into a corresponding compound of formula I,

In step (a), the subsequent reduction of the N-oxide of formula I obtained is advantageously carried out in a solvent such as water, water/ethanol, methanol, glacial acetic acid, ethyl acetate or dimethylformamide with hydrogen in the presence of a hydrogenation catalyst such as Raney nickel, platinum or palladium/charcoal, with metals such as iron, tin or zinc in the presence of an acid such as acetic, hydrochloric or sulphuric acid, with salts such as iron(II)sulphate, tin(II)chloride or

sodium dithionite, or with hydrazine in the presence of Raney nickel at temperatures between 0 and 50°C, but preferably at ambient temperature.

The reaction of step (b) is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, diethylether, tetrahydrofuran, dioxane, dimethyl-sulphoxide, dimethylformamide or benzene, optionally in the presence of an acid binding agent such as sodium carbonate, potassium carbonate, sodium hydroxide, potassium tert.-butoxide, triethylamine or pyridine, whilst the latter two may simultaneously also be used as solvent, preferably, at temperatures between 0 and 100°C, e.g. at temperatures between ambient temperature and 50°C.

In the reaction of step (b), a mixture of the 1- and 3-isomers is preferably obtained which can if desired subsequently be resolved into the corresponding 1- and 3-isomers, preferably by chromatography using a substrate such as silica gel or aluminium oxide.

In reaction step (c), functional derivatives of the carboxy group such as unsubstituted or substituted amides, esters, thioesters, orthoesters, iminoethers, amidines or anhydrides, a nitrile group or a tetrazolyl group may be converted into a carboxy group by hydrolysis, esters with tertiary alcohols, e.g. tert.butylester, may be converted into a carboxy group by thermolysis and esters with aralkanols, e.g. benzylester, may be converted into a carboxy group by hydrogenolysis.

The hydrolysis of step (c) is conveniently carried out in the presence of an acid such as hydrochloric, sulphuric, phosphoric, trichloroacetic or trifluoroacetic acid in the presence of a base such as

sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water/methanol, ethanol, water/ethanol, water/isopropanol or water/dioxane at temperatures between -10°C and 120°C , e.g. at temperatures between ambient temperature and the boiling temperature of the reaction mixture. When hydrolysis is carried out in the presence of an organic acid such as trichloroacetic or trifluoroacetic acid, any alcoholic hydroxy groups present may optionally be simultaneously converted into a corresponding acyloxy group such as a trifluoroacetoxy group.

If R_4' in a compound of formula V represents a cyano or aminocarbonyl group, these groups may also be converted into a carboxy group with a nitrite, e.g. sodium nitrite, in the presence of an acid such as sulphuric acid, which may also be simultaneously used as solvent, at temperatures between 0 and 50°C .

If R_4' in a compound of formula V represents, for example, a tert.-butoxycarbonyl group, the tert.-butyl group may also be thermally cleaved, optionally in an inert solvent such as methylene chloride, chloroform, benzene, toluene, tetrahydrofuran or dioxane and preferably in the presence of a catalytic amount of an acid such as p-toluenesulphonic acid, sulphuric, phosphoric or polyphosphoric acid, preferably at the boiling temperature of the solvent used, e.g. at temperatures between 40°C and 100°C .

If R_4' in a compound of formula V represents, for example, a benzyloxycarbonyl group, the benzyl group may also be hydrogenolytically cleaved in the presence of a hydrogenation catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethanol/water, glacial acetic acid, ethyl acetate, dioxane or dimethylformamide, preferably at temperatures

between 0 and 50°C, e.g. at ambient temperature, under a hydrogen pressure of 1 to 5 bar. During hydrogenolysis, other groups may be reduced at the same time, e.g. a nitro group may be reduced to an amino group, a benzyloxy group to a hydroxy group, a vinylidene group to the corresponding alkylidene group or a cinnamic acid group to the corresponding phenyl-propionic acid group, or they may be replaced by hydrogen atoms, e.g. a halogen may be replaced by a hydrogen atom.

Suitable protecting groups for step (d) include, for example, triphenylmethyl, tributyl tin or triphenyl tin groups.

In step (d), the cleaving of a protective group used is advantageously carried out in the presence of a hydrohalic acid, preferably in the presence of hydrochloric acid, in the presence of a base such as sodium hydroxide or alcoholic ammonia, in a suitable solvent such as methylene chloride, methanol, methanol/ammonia, ethanol or isopropanol at temperatures between 0 and 100°C, but preferably at ambient temperature or, if the reaction is carried out in the presence of alcoholic ammonia, at elevated temperatures, e.g. at temperatures between 200 and 150°C, preferably at temperatures between 120 and 140°C.

The reaction of step (e) is preferably carried out in a solvent such as benzene, toluene or dimethylformamide at temperatures between 80 and 150°C, preferably at 125°C. Conveniently, either the hydrazoic acid is liberated during the reaction from an alkali metal azide, e.g. sodium azide, in the presence of a weak acid such as ammonium chloride or a tetrazolide salt obtained in the reaction mixture during the reaction with a salt of hydrazoic acid, preferably with aluminium azide or tributyl tin azide, which is also preferably produced in


the reaction mixture by reacting aluminium chloride or tributyl tin chloride with an alkali metal azide such as sodium azide, is subsequently liberated by acidification with a dilute acid such as 2N hydrochloric or 2N sulphuric acid.

The reaction of step (f) is expediently carried out in a solvent or mixture of solvents such as ethanol, isopropanol, benzene, glycol, glycolmonomethylether, dimethyl-formamide or dioxane, e.g. at temperatures between 0 and 150°C, preferably at temperatures between 20 and 100°C. However, the reaction may also be carried out without solvents.

The cyclisation of step (g) is conveniently carried out in a solvent or mixture of solvents such as ethanol, isopropanol, glacial acetic acid, benzene, chlorobenzene, toluene, xylene, glycol, glycolmonomethylether, diethyleneglycol-dimethylether, sulfolan, dimethylformamide, tetralin or in an excess of the acylating agent used to prepare the compound of general formula X, e.g. in the corresponding nitrile, anhydride, acid halide, ester or amide, e.g. at temperatures between 0 and 250°C, but preferably at the boiling temperature of the reaction mixture, optionally in the presence of a condensing agent such as phosphorus oxychloride, thionylchloride, sulphurylchloride, sulphuric acid, p-toluenesulphonic acid, methanesulphonic acid, hydrochloric acid, phosphoric acid, polyphosphoric acid, acetic acid anhydride or optionally in the presence of a base such as potassium ethoxide or potassium tert.-butoxide. However, the cyclisation may also be carried out without a solvent and/or condensing agent.

However, it is particularly advantageous to perform the reaction of step (g) by preparing a compound of formula

X in the reaction mixture by reducing a corresponding o-nitro-amino compound, optionally in the presence of a carboxylic acid of formula XI



(wherein

R_1 , R_3 and R_4 are defined as hereinbefore), or by acylating a corresponding o-diamino compound with a carboxylic acid of formula XI.

When the reduction of the nitro group is broken off at the hydroxylamine stage, subsequent cyclisation produces the N-oxide of a compound of formula I. The N-oxide thus obtained is then converted by reduction into a corresponding compound of formula I.

The subsequent reduction of an N-oxide thus obtained is preferably carried out in a solvent such as water, water/ethanol, methanol, glacial acetic acid, ethyl acetate or dimethylformamide with hydrogen in the presence of a hydrogenation catalyst such as Raney nickel, platinum or palladium/charcoal, with metals such as iron, tin or zinc in the presence of an acid such as acetic, hydrochloric or sulphuric acid, with salts such as iron(II)sulphate, tin(II)chloride or sodium dithionite, or with hydrazine in the presence of Raney nickel at temperatures between 0 and 50°C, but preferably at ambient temperature.

The subsequent hydrolysis in step (g) is conveniently carried out either in the presence of an acid such as hydrochloric, sulphuric, phosphoric, trichloroacetic or

trifluoroacetic acid in the presence of a base such as sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water/methanol, ethanol, water/ethanol, water/isopropanol or water/dioxane at temperatures between -10°C and 120°C , e.g. at temperatures between ambient temperature and the boiling temperature of the reaction mixture. When hydrolysis is carried out in the presence of an organic acid such as trichloroacetic or trifluoroacetic acid, any alcoholic hydroxy groups present may simultaneously be converted into a corresponding acyloxy group such as the trifluoroacetoxy group.

The reaction of step (h) is conveniently carried out in a solvent such as methanol, ethanol, isopropanol, glacial acetic acid or propionic acid and/or in an excess of the hydrazine or hydrazine hydrate used at temperatures between 0 and 200°C , e.g. at temperatures between 20 and 150°C , but preferably at the boiling temperature of the reaction mixture, and optionally in the presence of an acid such as sulphuric or p-toluenesulphonic acid as condensing agent. The reaction may, however, also be carried out without a solvent.

In step (i), examples of protecting groups for a hydroxy group are trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert.-butyl, benzyl and tetrahydropyranyl groups and protecting groups for an amino, alkylamino or imino group include the acetyl, benzoyl, ethoxycarbonyl and benzyl groups.

Step (i) is preferably carried out by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as hydrochloric or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide at temperatures between

0 and 100°C, preferably at the boiling temperature of the reaction mixture. However, a benzyl group is preferably split off by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 50°C, but preferably at ambient temperature, under a hydrogen pressure of 1 to 7 bar, preferably 3 to 5 bar.

An isomer mixture of a compound of formula I thus obtained may if desired be resolved according to step (j) by chromatography using a substrate such as silica gel or aluminium oxide,

In step (k), the compounds of formula I obtained may be converted into the acid addition salts thereof, more particularly for pharmaceutical use the physiologically acceptable salts thereof with inorganic or organic acids. Suitable acids for this purpose include hydrochloric, hydrobromic, sulphuric, phosphoric, fumaric, succinic, lactic, citric, Tartaric or maleic acid,

Furthermore, the new compounds of formula I thus obtained, if they contain a carboxy or 1H-tetrazolyl group, may if desired subsequently be converted into the salts thereof with inorganic or organic bases, more particularly for pharmaceutical use into the physiologically acceptable addition salts thereof. Suitable bases include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

The compounds of formulae II to XIII which are used as starting materials in the preparation of compounds of

formula I are either known **from** the literature or may be obtained **by** known methods.

Thus, **for** example, a compound **of** formula **II** may be obtained by alkylation of a corresponding o-amino-nitro compound and subsequent reduction of the nitro group.

A **compound of** formula **III, V, VI, VII, IX, X or XII** used as a starting material may be obtained by acylation of a corresponding o-phenylenediamine or a corresponding o-amino-nitro compound, followed by reduction of the nitro group and cyclisation **of** the subsequently obtained o-diamino-phenyl compound, optionally followed by cleaving any protecting group used or by cyclisation of a correspondingly substituted benzimidazole with a corresponding **amine** or by NH-alkylation of a corresponding **1H-benzimidazole**, whilst the isomer **mixture** thus obtained may **then** be resolved by **conventional** methods, **e.g.** chromatography. **Some** of the starting compounds mentioned above are described in EP-A-392317.

For example, **2-n-propyl-5-(imidazo[1,2-a]pyridin-2-yl)-3H-benzimidazole** is obtained by reacting p-amino-acetophenone with butyric acid chloride, followed by nitration, bromination, cyclisation with 2-aminopyridine to form the 6-n-butanoylamido-3-(imidazo[1,2-a]pyridin-2-yl)-nitrobenzene, which is subsequently converted into the desired compound by cyclisation, after reduction of the **nitro** group, or

2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-1H-benzimidazole may be obtained by nitration of methyl 3-methyl-4-n-butanoylamido-benzoate, subsequent reduction of the nitro **group** and cyclisation to **yield** 2-n-propyl-4-methyl-6-methoxycarbonyl-1H-benzimidazole, which is **then converted into the desired compound using 2-methylamino-**



aniline with cyclisation.

A benzimidazole in which the alkoxy group is substituted in the 2-, 3-, 4- or 5-position by an imidazole group may be obtained for example by reaction of a corresponding 7-hydroxy-benzimidazole, as described in EP-A-392317, by reaction with a corresponding α , ω -dihaloalkane and subsequent reaction with a corresponding imidazole.

The new compounds of formula I and the physiologically acceptable salts thereof have valuable pharmacological properties. They are angiotensin antagonists, particularly angiotensin-II-antagonists.

By way of example, the following compounds were tested for their biological effects as described hereinafter:

A = 4'-[[2-n-butyl-7-[3-(imidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

B = 4'-[[2-n-butyl-7-[3-(benzimidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid trifluoroacetate;

C = 4'-[[2-n-butyl-4-methyl-7-[4-(tetrahydro-benzimidazol-1-yl)-butoxy]-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

D = 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

E = 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

- F = 4'-[[2-n-propyl-4-methyl-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;
- G = 4'-[[2-n-propyl-4-methyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;
- H = 4'-[[2-n-butyl-6-(2,3-dimethylmaleic acid imino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid semihydrate;
- I = 4'-[[2-n-butyl-6-(isopropylcarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;
- J = 4'-[[2-n-butyl-4-methyl-6-(morpholinocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;
- K = 4'-[[2-n-butyl-6-(cyclohexylaminocarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid semitrifluoroacetate;
- L = 4'-[[2-n-butyl-7-[3-(imidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;
- M = 4'-[(2-cyclopropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid;
- W = 4'-[(2-n-propyl-4-methyl-6-(1-methyl-5-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid;
- O = 4'-[(2-n-propyl-4-methyl-6-

(imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

P = 4'-[(2-n-propyl-4-methyl-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid;

Q = 4'-[(2-n-propyl-4-methyl-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

R = 4'-[(2-n-propyl-4-chloro-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl-hydrochloride; and

S = 4'-[[2-n-propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid.

Description of method: Angiotensin II-receptor bonding

The tissue (rats lung) is homogenised in Tris-buffer (50 mMol Tris, 150 mMol NaCl, 5 mMol EDTA, pH 7.40) and centrifuged twice for 20 minutes at 20,000 x g. The finished pellets are resuspended in incubating buffer (50 mMol Tris, 5 mMol MgCl₂, 0.2% BSA, pH 7.40) 1:75, based on the moist weight of the tissue. Each 0.1 ml of homogenate is incubated for 60 minutes at 37°C with 50 pM [¹²⁵I]-angiotensin II (NEN, Dreieich, FRG) with increasing concentrations of the test substance in a total volume of 0.25 ml. Incubation is ended by rapid filtration through glass fibre filter mats. The filters are each washed with 4 ml of ice cold buffer (25 mMol Tris, 2.5 mMol MgCl₂, 0.1% BSA, pH 7.40). The bound radioactivity is measured using a gamma-counter. The

corresponding IC_{50} value is obtained from the dose-activity curve.

In the test described, substances A to S show the following IC_{50} values:

| Substance | IC_{50} [nM] |
|-----------|----------------|
| A | 510.0 |
| B | 52.0 |
| C | 130.0 |
| D | 3.7 |
| E | 14.0 |
| F | 5.0 |
| G | 1.2 |
| H | 20.0 |
| I | 6.6 |
| J | 3.5 |
| K | 17.0 |
| L | 240.0 |
| M | 12.0 |
| N | 26.0 |
| O | 3.4 |
| P | 1.2 |
| Q | 1.7 |
| R | 20.0 |
| S | 7.8 |

In addition, compounds D, E, F, G, H, M and O were tested on conscious renally hypertensive rats for their effect after oral administration using methods known from the literature. At a dosage of 10 mg/kg these compounds exhibited a hypotensive effect.

Moreover, when the above-mentioned compounds were administered in a dose of 30 mg/kg i.v. no toxic side effects, e.g. negative inotropic effects or disorders in heart rhythm, were observed. The compounds are

therefore well tolerated.

In view of their pharmacological properties, the new compounds and the physiologically acceptable addition salts thereof are suitable for the treatment of hypertension and cardiac insufficiency and also for treating ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), for the prevention of the progression of cardiac insufficiency after myocardial infarction and for treating diabetic nephropathy, glaucoma, gastrointestinal diseases and bladder diseases.

The new compounds and the physiologically acceptable addition salts thereof are also suitable for treating pulmonary diseases, e.g. lung oedema and chronic bronchitis, for preventing arterial re-stenosis after angioplasty, for preventing thickening of blood vessel walls after vascular operations, and for preventing arteriosclerosis and diabetic angispathy. In view of the effects of angiotensin on the release of acetylcholine and dopamine in the brain, the new angiotensin antagonists are also suitable for alleviating central nervous system disorders, e.g. depression, Alzheimer's disease, Parkinson syndrome, bulimia and disorders of cognitive function.

Viewed from a further aspect, the present invention provides the use of a compound of formula I or an isomer or physiologically acceptable salt thereof for the manufacture of a therapeutic composition with an angiotensin antagonistic activity.

In particular the present invention provides the use of a compound of formula I or an isomer or physiologically acceptable salt thereof for the manufacture of a therapeutic composition to treat hypertension, pulmonary

diseases, **cardiac** insufficiency, ischaemic **peripheral circulatory** disorders, myocardial ischaemia (angina), **diabetic** nephropathy, glaucoma, gastrointestinal and bladder diseases or to prevent the progression of cardiac insufficiency after myocardial infarction.

Additionally, the present invention provides the use of a compound of formula I or an isomer or physiologically acceptable salt thereof for the manufacture of a **therapeutic** composition to treat depression, **Alzheimer's** disease, Parkinson syndrome, bulimia, disorders of cognitive function as well as other central nervous system disorders.

Viewed from another aspect, the present invention provides a method of treatment of the human or non-human animal **body** said method **comprising** administering to said body a pharmaceutically acceptable form of a compound of formula I or an isomer or salt thereof,

In particular, the present invention provides a method of treatment of the human or non-human animal **body** said method **comprising** administering to said body a pharmaceutically acceptable form of a compound of formula I, wherein said body is suffering from hypertension, pulmonary diseases, cardiac insufficiency, ischaemic **peripheral** circulatory disorders, myocardial **ischaemia** (angina), diabetic nephropathy, glaucoma, gastrointestinal or bladder diseases or cardiac insufficiency after myocardial infarction.

The present invention also provides a method of treatment of the human or non-human animal **body** said method comprising administering to said body a pharmaceutically acceptable form of a compound of **formula I**, wherein said body is suffering from depression, **Alzheimer's** disease, Parkinson syndrome,

bulimia, disorders of cognitive function or other central nervous system disorders.

The dosage required to achieve these effects in adults is generally 20 to 100 mg, preferably 30 to 70 mg, when administered intravenously, or orally 50 to 200 mg, preferably 75 to 150 mg, administered 1 to 3 times a day. For this purpose, the compounds of formula I prepared according to the invention, optionally in conjunction with other active substances, such as hypotensives, diuretics and/or calcium antagonists, may be incorporated together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene-glycol, propylene-glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, in conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.

Additional active substances which may be included in the combinations mentioned above might be, for example, bendroflumethiazide, chlorothiazide, hydrochlorothiazide, spironolactone, benzothiazide, cyclothiazide, ethacrinic acid, furosemide, metoprolol, prazosine, atenolol, propranolol, (di)hydralazine-hydrochloride, diltiazem, felodipin, nicardipin, nifedipin, nisoldipin and nitrendipin. The dosage for these active substances is appropriately one fifth of the lowest recommended dose up to 1/1 of the normally recommended dose, i.e., for example, 15 to 200 mg of hydrochlorothiazide, 125 to 2000 mg of chlorsthiiazide, 15 to 200 mg of ethacrinic acid, 5 to 80 mg of furosemide, 20 to 489 mg of psopranolal, 5 to 60 mg of felodipine, 5 to 60 mg of

nifedipin or 5 to 60 mg of nitrendipin.

The invention is further illustrated by the following, non-limiting Examples. In the Examples (except where otherwise specified) all parts and ratios are given by weight, except for eluant or solvent ratios which are by volume.

Example 1

4'-[[2-n-Butyl-7-[5-(imidazol-1-yl)-pentyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid hydrate

0.7 g (1.15 mMol) of tert.-butyl 4'-[[2-n-butyl-7-[5-(imidazol-1-yl)-pentyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate are dissolved in 35 ml of methylene chloride, 5 ml of trifluoroacetic acid are added and the mixture is stirred for 12 hours at ambient temperature. It is diluted with methylene chloride and extracted with water and with saturated sodium bicarbonate solution. The organic phase is dried over sodium sulphate and evaporated down in vacuo. The crude product thus obtained is purified over a silica gel column (particle size: 0.063-0.02 mm, ethyl acetate/ethanol/ammonia - 90:10:0.1) and crystallised from acetone.

Yield: 0.19 g (29.9% of theory),

Melting point: 185-187°C

$C_{34}H_{38}N_4O_3 \times H_2O$ (550.70)

Calculated: C 71.81 H 7.09 N 9.85

Found: 72.03 7.19 9.71

Mass spectrum: m/e = M 550

The following compounds are obtained analogously to Example 1:

4'-[[2-n-butyl-4-methyl-6-(4,5-dihydro-2H-pyridazin-3-on-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(4,5-dihydro-2H-pyridazin-3-on-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-ethyl-4-methyl-6-(4,5-dihydro-2H-pyridazin-3-on-

6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-4-methyl-6-(phenylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-ethyl-4-methyl-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-4-methyl-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(methylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(n-pentylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(n-pentylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(n-butylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(benzylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(allylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(cyclohexylaminocarbonyl-methylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(dimethylaminocarbonyl-methylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(dimethylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(cyclohexylaminocarbonyl-n-butylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(methylaminocarbonyl-cyclohexylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(methylaminocarbonyl-benzylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(n-hexylaminocarbonyl-cyclohexylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(cyclohexylaminocarbonyl-ethylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(dimethylaminocarbonyl-n-pentylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(morpholinocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(pyrrolidinocarbonylamino)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(pyrrolidinocarbonyl-
methylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-
carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(piperidinocarbonylamino)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(3-benzyl-3,4,5,6-tetrahydro-
2(1H)-pyrimidinon-1-yl)-benzimidazol-1-yl]-methyl]-
biphenyl-2-carboxylic acid

Example 2

4'-[[2-n-Butyl-7-[3-(imidazol-1-yl)-propyloxy]-4-methyl-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-
[[2-n-butyl-7-[3-(imidazol-1-yl)-propyloxy]-4-methyl-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and
trifluoroacetic acid Sn methylene Chloride.

Yield: 69.4% of theory,

Melting point: 208-210°C

$C_{32}H_{34}N_4O_3$ (522.64)

Calculated! C 73.54 H 6.56 N 10.72

Found: 73.45 6.62 10.60

R_f value: 0.50 (silica gel; ethyl acetate/ethanol/ammonia
= 50:45:5)

Example 3

4'-[[2-n-Butyl-7-[3-(benzimidazol-1-yl)-propyloxy]-4-
methylbenzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic
acid trifluoroacetate

Prepared analogously to Example 1 from tert.-butyl 4'-

[[2-n-butyl-7-[3-(benzimidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 87.8% of theory,

Melting point: 221-223°C

$C_{36}H_{36}N_4O_3 \times CF_3COOH$ (686.72)

Calculated: C 66.46 H 5.43 N 8.15

Found: 66.58 5.62 8.31

R_f value: 0.45 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5)

Example 4

4'-[[2-n-Butyl-7-[4-(imidazol-1-yl)-butyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid hydrate

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-7-[4-(imidazol-1-yl)-butyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 68.5% of theory,

Melting point: 126-128°C

$C_{33}H_{36}N_4O_3 \times H_2O$ (554.68)

Calculated: C 71.46 H 6.91 N 10.10

Found: 71.63 7.02 9.98

Mass spectrum: $m/e = 536$

Example 5

4'-[[2-n-Butyl-7-[2-(benzimidazol-1-yl)-ethoxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-7-[2-(benzimidazol-1-yl)-ethoxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 78.1% of theory,

Melting point: 167-169°C

$C_{35}H_{34}N_4O_3$ (558.68)

Calculated: C 75.25 H 6.13 N 10.03

Found: 75.03 6.17 9.95

Example 6

4'-[[2-n-Butyl-7-[5-(benzimidazol-1-yl)-pentyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-7-[5-(benzimidazol-1-yl)-pentyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Example 7

4'-[[2-n-Butyl-7-[4-(benzimidazol-1-yl)-butyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-7-[4-(benzimidazol-1-yl)-butyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Example 8

4'-[[2-n-Butyl-4-methyl-7-[4-(tetrahydrobenzimidazol-1-yl)-butyloxy]-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-4-methyl-7-[4-(tetrahydrobenzimidazol-1-yl)-butyloxy]-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene

chloride.

Yield: 86% of theory,

Melting point: 229-231°C

$C_{37}H_{42}N_4O_3$ (590.76)

Calculated: C 75.23 H 7.17 N 9.48

Found: 75.34 7.06 9.38

Example 9

4'-[[2-n-Propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in dimethylformamide.

Yield: 63.9% of theory,

Melting point: 261-263°C

$C_{33}H_{30}N_4O_2$ (514.60)

Calculated: C 77.02 H 5.87 N 10.89

Found: 76.90 5.85 10.99

The following compounds are obtained analogously to Example 9:

4'-[[2-n-propyl-4-methyl-6-(1-n-propylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(1-n-hexylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(1-cyclopropylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(1-cyclohexylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Example 10

4'-[[2-n-Propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4.3 g (66 mMol) of sodium azide and 3.5 g (66 mMol) of ammonium chloride are added to a solution of 1.60 g (3.3 mMol) of 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl in 50 ml of dimethylformamide and the mixture is stirred for 24 hours at 140°C. Then water is added and the precipitate is removed by suction filtering. The crude product thus obtained is purified by chromatography over silica gel (300 g of silica gel, methylene chloride + 6% ethanol).

Yield: 900 mg (51% of theory),

Melting point: 228-230°C

$C_{33}H_{30}N_8$ (538.70)

Calculated: C 73.58 H 5.61 N 20.80

Found: 73.48 5.55 20.70

The following compounds are obtained analogously to Example 10:

4'-[[2-n-propyl-4-methyl-6-(1-n-hexylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(1-cyclobutylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(1-cyclohexylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-7-[2-(imidazol-1-yl)-ethoxy]-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-7-[3-(imidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-7-[4-(imidazol-1-yl)-butyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-7-[5-(imidazol-1-yl)-pentyloxy]-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-7-[2-(benzimidazol-1-yl)-ethoxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-7-[3-(benzimidazol-1-yl)-propyloxy]-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-7-[4-(benzimidazol-1-yl)-butyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-7-[5-(benzimidazol-1-yl)-pentyloxy]-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-7-[2-(4,5,6,7-tetrahydrobenzimidazol-1-yl)-ethoxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-7-[3-(tetrahydrobenzimidazol-1-yl)-propyloxy]-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-7-[4-(tetrahydrobenzimidazol-1-yl)-butyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-7-[5-(tetrahydrobenzimidazol-1-yl)-pentyloxy]-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(phenylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-ethyl-4-methyl-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-propyl-4-methyl-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(methylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(n-pentylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(n-pentylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(n-butylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(benzylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(allylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(cyclohexylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(dimethylaminocarbonylmethylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(dimethylaminocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(cyclohexylaminocarbonyl-n-butylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(methylaminocarbonylcyclohexylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(methylaminocarbonylbenzylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(n-hexylaminocarbonylcyclohexylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(cyclohexylaminocarbonyl-ethylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(dimethylaminocarbonyl-n-pentylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(morpholinocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(pyrrolidinocarbonylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(pyrrolidinocarbonyl-methylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(piperidinocarbonyl-methylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(3-benzyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinon-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 11

4'-[(2-n-Propyl-4-methyl-6-phthalimino-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-phthalimino-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 6.8% of theory,

Melting point: sintering from 160°C

C₃₃H₂₇N₇O₂ (553.60)

Calculated: C 71.59 H 4.92 N 17.71

Found: 71.39 4.88 17.54

Example 12

4'-[(2-n-Butyl-4-methyl-6-phthalimino-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-butyl-4-methyl-6-phthalimino-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 7.1% of theory,

Melting point: sintering from 150°C

$C_{34}H_{29}N_7O_2$ (567.70)

Calculated: C 71.94 H 5.15 N 17.27

Found: 71.75 5.19 17.22

Example 13

4'-[[2-n-Propyl-4-methyl-6-(1-oxo-isoindolin-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-4-methyl-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 25.0% of theory,

Melting point: sintering from 170°C

$C_{33}H_{29}N_7O$ (539.60)

Calculated: C 73.45 H 5.42 N 18.17

Found: 73.20 5.41 18.33

Example 14

4'-[[2-n-Butyl-4-methyl-6-(1-oxo-isoindolin-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-butyl-4-methyl-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 21.0% of theory,

Melting point: sintering from 165°C

$C_{34}H_{31}N_7O$ (553.70)

Calculated: C 73.76 H 5.64 N 17.71

Found: 73.58 5.33 17.41

Example 15

4'-[[2-n-Propyl-4-methyl-6-(butanesultam-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-4-methyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 49.0% of theory,

Melting point: Sintering from 186°C

C₂₉H₃₁N₇O₂S (541.70)

Calculated: C 64.30 H 5.77 N 18.10 S 5.92

Found: 64.10 5.39 18.01 5.98

Example 16

4'-[[2-Ethyl-4-methyl-6-(butanesultam-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-ethyl-4-methyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 60.0% of theory,

Melting point: amorphous, sintering from 194°C

C₂₈H₂₉N₇O₂S (527.70)

Calculated: C 63.74 H 5.54 N 18.58 S 6.08

Found: 63.83 5.66 18.41 5.82

Example 17

4'-[[2-n-Butyl-4-methyl-6-(butanesultam-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-butyl-4-methyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide,

Yield: 48.0% of theory,

Melting point: amorphous, sintering from 183°C

$C_{30}H_{33}N_7O_2S$ (555.70)

Calculated: C 64.84 H 5.99 N 17.64 S 5.77

Found: 64.53 5.66 17.63 5.55

Example 18

4'-[[2-n-Propyl-4-ethyl-6-(butanesultam-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-4-ethyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 27.0% of theory,

Melting point: amorphous, sintering from 189°C

$C_{30}H_{33}N_7O_2S$ (555.70)

Calculated: C 64.84 H 5.99 N 17.64 S 5.77

Found: 64.81 5.68 17.87 5.31.

Example 19

4'-[[2-Ethyl-4-ethyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-ethyl-4-ethyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 39.0% of theory,

Melting point: amorphous, sintering from 212°C

$C_{29}H_{31}N_7O_2S$ (541.70)

Calculated: C 64.30 H 5.77 N 18.10 S 5.92

Found: 64.30 5.51 17.99 5.59

Example 20

4'-[[2-n-Propyl-4-isopropyl-6-(butanesultam-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-4-isopropyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethyl-formamide.

Yield: 22.0% of theory,

Melting point: amorphous

C₃₁H₃₅N₇O₂S (569.70)

Calculated: C 65.35 H 6.19 N 17.21 S 5.63

Found: 65.13 6.10 17.54 5.40

Example 21

4'-[[2-Ethyl-4-isopropyl-6-(butanesultam-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-ethyl-4-isopropyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethyl-formamide.

Yield: 24.09 of theory,

Melting point: amorphous, sintering from 209°C

C₃₀H₃₃N₇O₂S (555.70)

Calculated: C 64.84 H 5.99 N 17.64 S 5.77

Found: 64.99 5.71 17.43 5.71

Example 22

4'-[[2-n-Propyl-4-trifluoromethyl-6-(butanesultam-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-4-trifluoromethyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in

dimethyl-formamide.

Yield: 17.0% of theory,

Melting point: 199-203°C

$C_{29}H_{28}F_3N_7O_2S$ (595.70)

Calculated: C 58.48 H 4.74 N 16.46

Found: 58.28 4.43 16.22

Example 23

4'-[[2-n-Propyl-4-methyl-6-(N-benzenesulphonyl-methylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-4-methyl-6-(N-benzenesulphonyl-methylamino)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 42.0% of theory,

Melting point: 161-163°C

$C_{32}H_{31}N_7O_2S$ (577.70)

Calculated: C 66.53 H 5.41 N 16.97 S 5.55

Found: 66.32 5.36 16.70 5.31

Example 24

4'-[[2-n-Butyl-4-methyl-6-(N-benzenesulphonyl-methylamino)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-butyl-4-methyl-6-(N-benzenesulphonyl-methylamino)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 37.0% of theory,

Melting point: 150-153°C

$C_{33}H_{33}N_7O_2S$ (591.70)

Calculated: C 66.98 H 5.62 N 16.54

Found: 66.71 5.38 16.39

The following compounds are obtained analogously to Example 24:

4'-[[2-ethyl-4-methyl-6-(4,5-dihydro-2H-pyridazin-3-on-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(4,5-dihydro-2H-pyridazin-3-on-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(4,5-dihydro-2H-pyridazin-3-on-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(3-benzyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinon-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-ethyl-4-methyl-6-(3-benzyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinon-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 25

4'-[[2-n-Butyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 48.0% of theory,

Melting point: 233-235°C

$C_{34}H_{32}N_4O_2$ (528.70)

Calculated: C 77.25 H 6.10 N 10.60

Found: 77.10 5.98 10.46

Example 26

4'-[[2-n-Butyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-butyl-
4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-
yl]-methyl]-2-cyano-biphenyl and sodium azide in
dimethylformamide.

Yield: 41.0% of theory,

Melting point: 235-237°C

C₃₄H₃₂N₈ (552.70)

Calculated: C 73.89 H 5.84 N 20.28

Found: 73.67 5.81 19.93

The following compounds are obtained analogously to
Example 26:

4'-[[2-n-butyl-4-methyl-6-(1-ethylbenzimidazol-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(1-cyclopropylbenzimidazol-2-
yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-
biphenyl

4'-[[2-n-butyl-4-methyl-6-(1-n-pentylbenzimidazol-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(1-cyclopentylbenzimidazol-2-
yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-
biphenyl

Example 27

4'-[[2-n-Propyl-4-methyl-6-(2-oxo-piperidin-1-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-

4-methyl-6-(2-oxo-piperidin-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and codium azide in dimethyl-formamide.

Yield: 51.0% of theory,

Melting point: amorphous, from 140°C (sintering)

$C_{30}H_{31}N_7O$ (505.60)

Calculated: C 71.26 H 6.18 N 19.39

Found: 71.08 6.22 19.47

Example 28

4'-[[2-n-Butyl-4-methyl-6-(2-oxo-piperidin-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-butyl-4-methyl-6-(2-oxo-piperidin-1-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethyl-formamide.

Yield: 39.0% of theory,

Melting point: amorphous, from 128°C (sintering)

$C_{31}H_{33}N_7O$ (519.70)

Calculated: C 71.65 H 6.40 N 18.87

Found: 71.44 6.23 18.59

Example 29

4'-[[2-n-Propyl-4-methyl-6-(2-oxo-piperidin-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared from 4'-[[2-n-propyl-4-methyl-6-(2-oxo-piperidin-1-yl)-benzimidazol-1-yl]-methyl]-2-(2-triphenylmethyl-tetrazol-5-yl)biphenyl by cleaving the triphenylmethyl group with methanolic hydrochloric acid.

Yield: 51.01 of theory,

Melting point: amorphous, sintering from 115°C

$C_{30}H_{31}N_7O$ (505.60)

Calculated: C 71.26 H 6.18 N 19.39

Found: 71.51 6.39 19.09

Example 30

4'-[[2-n-Propyl-6-(imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-
[[2-n-propyl-6-(imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and
trifluoroacetic acid in methylene chloride.

Yield: 54.0% of theory,

Melting point: 202-204°C

C₃₁H₂₆N₄O₂ (486.60)

Calculated: C 76.52 H 5.39 N 11.52

Found: 76.33 5.32 11.30

The following compounds may be prepared analogously to
Example 30:

4'-[[2-n-propyl-6-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-6-(6-methyl-imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-6-(5,7-dimethyl-imidazo[1,2-a]pyridin-2-
yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic
acid

4'-[[2-n-propyl-6-(6-aminocarbonyl-imidazo[1,2-a]-
pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-
carboxylic acid

4'-[[2-n-butyl-6-(6-chloro-imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-6-(imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-6-(imidazo[2,1-b]thiazol-6-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-6-(2,3-dimethyl-imidazo[2,1-b]thiazol-6-
yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic
acid

Example 31

4'-[[2-n-Butyl-6-(imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-
[[2-n-butyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-
1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic
acid in methylene chloride.

Yield: 41.0% of theory,

Melting point: 193-195°C

$C_{32}H_{28}N_4O_2$ (500.60)

Calculated: C 76.78 H 5.64 N 11.19

Found: 76.73 5.48 11.00

Example 32

4'-[[2-n-Propyl-6-(imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-
6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-
methyl]-2-cyano-biphenyl and sodium azide in
dimethylformamide,

Yield: 28.0% of theory,

Melting point: 187-189°C

$C_{31}H_{26}N_8$ (510.60)

Calculated: C 72.92 H 5.13 N 21.95

Found: 72.80 4.97 21.74

The following compounds may be prepared analogously to Example 32:

4'-[[2-n-propyl-6-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(5-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-6-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(5,7-dimethyl-imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-6-(3-methyl-imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(2-phenyl-imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 33

4'-[[2-n-Butyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-butyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 23.0% of theory,

Melting point: 170-173°C

N (524.60)

Calculated: C 73.26 H 5.38 N 21.36

Found: 73.09 5.32 21.20

Example 34

4'-[[2-n-Propyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 38.0% of theory,

Melting point: 195-197°C (after evaporation and without recrystallisation)

Melting point: 299-303°C (methylene chloride/ethanol = 20:1)

C₃₂H₂₈N₄O₂ (500.60)

Calculated: C 76.78 H 5.64 N 11.19

Found: 76.55 5.61 10.87

The following compounds may be prepared analogously to Example 34:

4'-[[2-n-propyl-4-methyl-6-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-4-methyl-6-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-4-methyl-6-(6-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(5-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-

biphenyl-2-carboxylic acid

4'-[[2-ethyl-4-methyl-6-(6-aminocarbonyl-imidazo-
[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-
biphenyl-2-carboxylic acid

4'-[[2-ethyl-4-methyl-6-(6-chloro-imidazo[1,2-a]pyridin-
2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic
acid

Example 35

4'-[[2-n-Propyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-
4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-
yl]-methyl]-2-cyano-biphenyl and sodium azide in
dimethylformamide.

Yield: 21.0% of theory,

Melting point: sintering from 181°C

N (524.60)

Calculated: C 73.26 H 5.38 N 21.36

Found: 73.10 5.24 21.13

The following compounds may be prepared analogously to
Example 35:

4'-[[2-n-propyl-4-methyl-6-(5-methyl-imidazo[1,2-a]-
pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-
5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyrimidin-2-
yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-
biphenyl

Example 36

4'-[[2-n-Butyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene Chloride.

Yield: 51.0% of theory,

Melting point: 194-197°C

$C_{33}H_{30}N_4O_2$ (514.60)

Calculated: C 77.02 H 5.88 N 10.89

Found: 76.81 5.78 10.64

The following compounds are obtained analogously to Example 36:

4'-[[2-n-propyl-6-(pyrrolidin-2-on-5-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-6-(pyrrolidin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-6-(quinolin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-6-(quinolin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-6-(isoquinolin-3-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-ethyl-6-(isoquinolin-3-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Example 37

4'-[[2-n-Butyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-butyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 26.0% of theory,

C₃₃H₃₀N₈ (538.60)

Calculated: C 73.58 H 5.61 N 20.80

Found: 73.39 5.40 20.92

The following compounds are obtained analogously to Example 37:

4'-[[2-n-propyl-6-(pyrrolidin-2-on-5-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(pyrrolidin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(piperidin-2-on-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-6-(piperidin-2-on-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(piperidin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-6-(piperidin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-ethyl-6-(pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-6-(pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(quinolin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-6-(quinolin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-6-(isoquinolin-3-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-ethyl-6-(isoquinolin-3-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 38

4'-[[2-n-Butyl-4-methyl-6-(2,2-dimethylpropionylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-4-methyl-6-(2,2-dimethylpropionylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Example 39

4'-[[2-n-Butyl-7-[2-(tetrahydrobenzimidazol-1-yl)-ethoxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-7-[2-(tetrahydrobenzimidazol-1-yl)-ethoxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene

chloride.

Yield: 81% of theory,

Melting point: 236-237°C

$C_{35}H_{38}N_4O_3$ (562.71)

Calculated: C 74.71 H 6.81 N 9.96

Found: 74.51 6.79 9.98

Example 40

4'-[[2-n-Butyl-4-methyl-7-[5-(tetrahydrobenzimidazol-1-yl)-pentyloxy]-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-4-methyl-7-[5-(tetrahydrobenzimidazol-1-yl)-pentyloxy]-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Example 41

4'-[[2-n-Butyl-7-[3-(tetrahydrobenzimidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-butyl-7-[3-(tetrahydrobenzimidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Example 42

4'-[[2-n-Propyl-4-methyl-6-(imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-

[[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 47% of theory,

Melting point: 224-226°C (after evaporation and without recrystallisation)

Melting point: 294-297°C (methylene chloride/ethanol = 20: 1)

$C_{31}H_{27}N_5O_2$ (501.60)

Calculated: C 74.23 H 5.43 N 13.96

Found: 74.10 5.31 13.66

Example 43

4'-[[2-n-Propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 43% of theory,

Melting point: 192-195°C (after evaporation and without recrystallisation)

Melting point: >300°C (methylene chloride/ethanol = 20:1)

$C_{30}H_{26}N_4O_2S$ (506.64)

Calculated: C 71.12 H 5.17 N 11.06 S 6.33

Found: 70.97 5.19 10.88 6.09

The following compounds may be prepared analogously to Example 43:

4'-[[2-n-propyl-4-methyl-6-(3-methyl-imidazo[2,1-b]-thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(2,3-dimethyl-imidazo[2,1-b]-thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-4-methyl-6-(2,3-trimethylene-imidazo-
[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-
biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(2,3-tetramethylene-
imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-
biphenyl-2-carboxylic acid

4'-[[2-ethyl-4-methyl-6-(2-phenyl-imidazo[2,1-b]-
thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-
carboxylic acid

Example 44

4'-[[2-n-Propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-
4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-
yl]-methyl]-2-cyano-biphenyl and sodium azide in
dimethylformamide.

Yield: 21% of theory,

Melting point: amorphous, sintering from 196°C

C₃₀H₂₆N₈S (530.67)

Calculated: C 67.90 H 4.94 N 21.12 S 6.04

Found: 67.77 4.84 21.00 5.87

The following compounds may be prepared analogously to
Example 44:

4'-[[2-n-propyl-4-methyl-6-(3-methyl-imidazo[2,1-b]-
thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-
5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(2,3-dimethyl-imidazo[2,1-b]-
thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-
5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(2,3-trimethylene-imidazo-
[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-
tetrazol-5-yl)-biphenyl

4'-[[2-ethyl-4-methyl-6-(2,3-tetramethylene-imidazo-
[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-
tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(2-phenyl-imidazo[2,1-b]-
thiazol-6-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-
5-yl)-biphenyl

Example 45

4'-[[2-n-Propyl-4-methyl-6-(benzimidazol-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-
4-methyl-6-(benzimidazol-2-yl)-benzimidazol-1-yl]-
methyl]-2-cyano-biphenyl and sodium azide in dimethyl-
formamide.

Yield: 28% of theory,

Meltfng point: 202-205°C

C₃₂H₂₈N₄ (524.64)

Calculated: C 73.26 H 5.38 N 21.36

Found: 13.01 5.22 21.56

The following compounds are obtained analogously to
Example 45:

4'-[[2-ethyl-4-methyl-6-(benzimidazol-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-butyl-4-methyl-6-(benzimidazol-2-yl)-
benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(1-n-hexyl-benzimidazol-2-
yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-

biphenyl

4'-[[2-n-propyl-4-methyl-6-(1-cyclopropyl-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[[2-n-propyl-4-methyl-6-(1-cyclohexyl-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 46

4'-[[2-n-Propyl-4-methyl-6-(benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.-butyl 4'-[[2-n-propyl-4-methyl-6-(benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 43% of theory,

Melting point: 239-242°C

C₃₂H₂₈N₄O₂ (500.61)

Calculated: C 76.78 H 5.64 N 11.19

Found: 76.55 J. 60 11.41

The following compounds are obtained analogously to Example 46:

4'-[[2-ethyl-4-methyl-6-(benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-butyl-4-methyl-6-(benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(1-n-hexyl-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(1-cyclopropyl-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

4'-[[2-n-propyl-4-methyl-6-(1-cyclohexyl-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Example 47

4'-[[2-n-Butyl-7-[3-(imidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared from 4'-[[2-n-butyl-7-[3-(imidazol-1-yl)-propyloxy]-4-methyl-benzimidazol-1-yl]-methyl]-2-(1-triphenylmethyl-tetrazol-5-yl)-biphenyl by cleaving the 1-triphenylmethyl group by means of ethanol/hydrochloric acid.

Yield: 89.8% of theory,

Melting point: 83-87°C

$C_{32}H_{34}N_8O \times 1.5 H_2O$ (573.69)

Calculated: C 66.99 H 6.50 N 19.53

Found: 66.83 6.52' 19.43

Example 48

4'-[[6-(N-Benzenesulphonyl-methylamino)-2-n-butyl-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[[6-(N-benzenesulphonylmethylamino)-2-n-butyl-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 95.6% of theory,

Melting point: 211-212°C

$C_{33}H_{33}N_3O_4S$ (567..70)

Calculated: G 69.80 H 5.86 N 7.40 S 5.65

Found: 69.52 5.92 7-33 5.84

Example 49

4'-[[6-(N-Benzenesulphonyl-n-pentylamino)-2-n-butyl-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[[6-(N-benzenesulphonyl-n-pentylamino)-2-n-butyl-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 81.8% of theory,

Melting point: 232-233°C

$C_{37}H_{41}N_3O_4S$ (623.81)

Calculated: C 71.24 H 6.62 N 6.74 S 5.14

Found: 71.30 6.77 6.68 5.33

Example 50

4'-[[2-n-Butyl-6-(isopropylcarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[[2-n-butyl-6-(isopropylcarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 86.3% of theory,

Melting point: 313-315°C

$C_{30}H_{33}N_3O_3$ (483.61)

Calculated: C 74.51 H 6.88 N 8.69

Found: 74.37 7.10 8.74

Example 51

4'-[[2-n-Butyl-6-(2,3-dimethylmaleic acid imino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid-semihydrate

Prepared analogously to Example 1 from tert.butyl 4'-

[[2-n-butyl-6-(2,3-dimethylmaleic acid imino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 88.9% of theory,

Melting point: 321-322°C

$C_{32}H_{31}N_3O_4 \times 0.5 H_2O$ (530.62)

Calculated: C 72.43 H 6.08' N 7.92

Found: 72.89 6.16 7.89

Example 52

4'-[[6-(2,3-Dimethylmaleic acid imino)-2-n-propyl-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid semihydrate

Prepared analogously to Example 1 from tert.butyl 4'-[[6-(2,3-dimethylmaleic acid imino)-2-n-propyl-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 75.4% of theory,

Melting point: 329-331°C

$C_{31}H_{29}N_3O_4 \times 0.5 H_2O$ (516.60)

Calculated: C 72.08 H 5.85 N 8.13

Found: 72.04 5.84 7.96

Example 53

4'-[(6-Acetamino-2-n-butyl-4-methyl-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid trifluoroacetate semihydrate

Prepared analogously to Example 1 from tert.butyl 4'-[(6-acetamino-2-n-butyl-4-methyl-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 95.7% of thesry,

Melting point: 112-114°C (amorphous)

$C_{28}H_{29}N_3O_3 \times CF_3COOH \times 0.5 H_2O$ (578.59)

| | | | |
|-------------|---------|--------|--------|
| Calculated: | C 62.28 | H 5.40 | N 7.26 |
| Found: | 62.57 | 5.46 | 7.21 |

Example 54

4'-[[2-n-Butyl-4-methyl-6-(morpholinocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[[2-n-butyl-4-methyl-6-(morpholinocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 80.9% of theory,

Melting point: 279-281°C

$C_{31}H_{34}N_4O_4$ (526.64)

| | | | |
|-------------|---------|--------|---------|
| Calculated: | C 70.70 | H 6.51 | N 10.64 |
|-------------|---------|--------|---------|

| | | | |
|--------|-------|------|-------|
| Found: | 70.48 | 6.50 | 10.51 |
|--------|-------|------|-------|

Example 55

4'-[[2-n-Butyl-6-(cyclohexylaminocarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid semitrifluoroacetate

Prepared analogously to Example 1 from tert.butyl 4'-[[2-n-butyl-6-(cyclohexylaminocarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride,

Yield: 76.9% of theory,

Melting point: 288-289°C

$C_{33}H_{38}N_4O_3 \times 0.5 CF_3COOH$ (595.70)

| | | | |
|-------------|---------|--------|--------|
| Calculated: | C 68.55 | H 6.51 | N 9.41 |
|-------------|---------|--------|--------|

| | | | |
|--------|-------|------|------|
| Found: | 69.08 | 7.02 | 9.65 |
|--------|-------|------|------|

Example 56

4'-[[2-n-Propyl-4-isopropyl-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[[2-n-propyl-4-isopropyl-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl]-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 14% of theory,

Melting point: amorphous

$C_{35}H_{33}N_7O$ (567.71)

Calculated: C 74.05 H 5.86 N 17.27

Found: 73.97 5.82 17.26

Mass spectrum: $M^+ = 567$

Example 57

4'-[[2-n-Propyl-5-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[[2-n-propyl-5-(imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 32% of theory,

Melting point: 250-253°C

$C_{31}H_{26}N_4O_2$ (486.60)

Calculated: C 76.52 H 5.39 N 11.52

Found: 76.28 5.47 11.27

Example 58

4'-[(2-n-Propyl-4-ethyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-ethyl-6-(1-methylbenzimidazol-2-yl)-

benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 64% of theory,

Melting point: 217-219°C

$C_{34}H_{32}N_4O_2$ (528.70)

Calculated: C 77.24 H 6.10 N 10.60

Found: 77.12 6.09 10.75

Example 59

4'-[(2-n-Propyl-4-ethyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-ethyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 15% of theory,

Melting point: 215-217°C

$C_{34}H_{32}N_8$ (552.70)

Calculated: C 73.89 H 5.84 N 20.28

Found: 73.66 6.02 20.56

Example 60

4'-[(2-Cyclopropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-cyclopropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 52% of theory,

Melting point: 244-246°C

$C_{33}H_{28}N_4O_2$ (512.60)

Calculated: C 77.32 H 5.51 N 10.93

Found: 77.75 5.71 10.94

Example 61

4'-[(2-Cyclopropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-cyclopropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 59% of theory,

Melting point: 245-247°C

$C_{33}H_{28}N_8$ (536.65)

Calculated: C 73.86 H 5.26 N 20.88

Found: 73.95 5.42 20.90

Example 62

4'-[(2-Cyclobutyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-cyclobutyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 63% of theory,

Melting point: 189-191°C

$C_{34}H_{30}N_4O_2$ (526.60)

Calculated: C 77.55 H 5.74 N 10.64

Found: 77.35 5.92 10.40

Example 63

4'-[(2-Cyclobutyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-cyclobutyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 61% of theory,

Melting point: 197-199°C

C (550.70)

Calculated: C 74.16 H 5.49 N 20.35

Found: 74.12 5.74 20.67

Example 64

4'-[(2-n-Propyl-4-methyl-6-(1-methyl-5-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-methyl-6-(1-methyl-5-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 34% of theory,

Melting point: 250-252°C

C₃₃H₂₉FN₄O₂ (532.60)

Calculated: C 74.42 H 5.49 N 10.52

Found: 74.14 5.64 10.54

The following compounds are obtained analogously to Example 64:

4'-[(2-n-propyl-4-methyl-6-(pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(quinolin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(isoquinolin-3-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(isoquinolin-1-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Example 65

4'-[(2-n-Propyl-4-methyl-6-(imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 16.5% of theory,

Melting point: from 275°C (decomp.)

$C_{31}H_{27}N_9 \times H_2O$ (543.65)

Calculated: C 68.49 H 5.38 N 23.19

Found: 68.25 5.50 23.37

The following compounds are obtained analogously to Example 65:

4'-[(2-n-propyl-4-methyl-6-(pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[(2-n-propyl-4-methyl-6-(quinolin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[(2-n-propyl-4-methyl-6-(isoquinolin-3-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[(2-n-propyl-4-methyl-6-(isoquinolin-1-yl)-

benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 66

4'-[(2-n-Propyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 67% of theory,

Melting point: from 240°C (sinters)

$C_{32}H_{32}N_4O_2$ (504.64)

Calculated: C 76.16 H 6.39 N 11.10

Found: 75.94 6.46 11.20

The following compounds are obtained analogously to Example 66:

4'-[(2-n-butyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Example 67

4'-[(2-n-Propyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-

yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 73.5% of theory,

Melting point: from 275°C (decomp.)

$C_{32}H_{32}N_8$ (528.67)

Calculated.: C 72.70 H 6.10 N 21.20

Found: 72.40 6.07 21.48

The following compounds are obtained analogously to Example 67:

4'-[(2-n-butyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo-[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[(2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo-[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 68

4'-[(2-n-Propyl-4-methyl-6-(1-methyl-6-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-methyl-6-(1-methyl-6-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 76% of theory,

Melting point: 243-245°C

$C_{33}H_{29}FN_4O_2$ (532.60)

Calculated: 74.42 H 5.49, N 10.52

Found: 74.74 5.52 10.77

Mass spectrum: m/e = 532

Example 69

4'-[(2-n-Propyl-4-chloro-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-chloro-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 7.5% of theory,

Melting point: 209-210°C

$C_{32}H_{26}ClN_3O_3$ (536.04)

Mass spectrum: m/e = 535/537

R_f value: 0.25 (silica gel; methylene chloride/ethanol = 9:1)

Example 70

4'-[(2-n-Propyl-4-chloro-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-chloro-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 52.7% of theory,

Melting point: 292-295°C

$C_{32}H_{27}CN_4O_2$ (535.06)

R_f value: 0.30 (silica gel; methylene chloride/ethanol = 19:1)

Calculated: C 71.90 H 5.08 N 10.45 Cl 6.63

Found: 72.29 5.21 10.40 6.76

Example 71

4'-[(2-n-Propyl-4-chloro-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl hydrochloride

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-chloro-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 54.8% of theory,

Melting point: sintering from 204°C

$C_{32}H_{27}ClN_5 \cdot x HCl$ (595.55)

R_f value: 0.20 (silica gel; petroleum ether/ethyl acetate = 1:1 and 1% glacial acetic acid)

Calculated: C 62.55 H 4.71 N 18.85 Cl 11.85

Found: 62.34 4.97 18.84 11.57

Example 72

4'-[(2-n-Propyl-4-chloro-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-chloro-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 24.6% of theory,

Melting point: 246-248°C

$C_{32}H_{26}ClN_7O$ (560.08)

R_f value: 0.15 (silica gel; methylene chloride/ethanol = 9:1)

Calculated: C 69.00 H 4.67 N 17.55 Cl 6.40

Found: 68.26 4.75 17.73 6.97

The following compound is obtained analogously to Example 72:

4'-[(2-n-propyl-4-methyl-6-(4-methyl-imidazol-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 73

4'-[(2-n-Propyl-4-chloro-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-chloro-6-(cyclohexylaminocarbonylamino)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 75% of theory,

Melting point: 222-224°C

$C_{31}H_{33}ClN_4O_3$ (545.09)

R_f value: 0.15 (silica gel; methylene chloride/ethanol = 19: 1)

Calculated: C 68.50 H 6.10 N 10.30 Cl 6.48

Found: 68.89 5.98 10.02 7.04

Example 74

4'-[(2-n-Propyl-4-methyl-6-amidino-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid hydrate

a) Methyl 4'-[(2-n-propyl-4-methyl-6-amidino-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate

2.1 g (5 mMol) of methyl 4'-[(2-n-propyl-4-methyl-6-cyano-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate are dissolved in 250 ml of methanol at ambient temperature with stirring. Hydrogen chloride is introduced at 10-20°C for 3 hours whilst cooling with ice. The mixture is then stirred for a further 3 hours at ambient temperature. The solvent is distilled off in vacuo, the residue is twice mixed with ether and concentrated by evaporation. The imino ether formed is

taken up in 250 ml of methanol and mixed with 10.0 g of ammonium carbonate. The reaction mixture is stirred for 12 hours at ambient temperature. After the solvent has been removed in vacuo the residue is purified over a silica gel column (particle size 0.063-0.032 mm), using as eluant mixtures of methylene chloride and methanol of increasing polarity (9:1 and 8:2). The uniform fractions are evaporated down in vacuo.

Yield: 1.5 g (58% of theory)

R_f value: 0.15 (silica gel; eluant: methylene chloride/methanol = 9:1)

b) 4'-[(2-n-Propyl-4-methyl-6-amidino-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

0.51 g (1.0 mMol) of methyl 4'-[(2-n-propyl-4-methyl-6-amidino-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate are dissolved in 6 ml of tetrahydrofuran. 2.8 ml of 1.4 M aqueous lithium hydroxide solution and 3 ml of water are added and the mixture is stirred for 2 days at ambient temperature. Then a solution of 300 mg of ammonium chloride in 4 ml of water is added. After the mixture is stirred for 5 minutes, the precipitate formed is suction filtered, washed with acetone and dried over potassium hydroxide.

Yield: 6.25 g (59% of theory),

Melting point: 270-271°C (decomp.)

C₂₆H₂₆N₄O₂ x H₂O (426.53)

Calculated: C 70.25 H 6.35 N 12.60

Found: 70.04 6.23 12.50

R_f value: 0.55 (silica gel; eluant: methylene chloride/methanol/ammonia = 2:1:0.25)

The following compound is obtained analogously to Example 74:

4'-[(2-n-propyl-4-methyl-6-(3-methyl-imidazol-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Example 75

4'-[(2-n-Propyl-4-methyl-6-(1-methyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

a) 3-Methyl-4-butyrylamino-5-nitro-acetophenone

32.6 g (148 mmol) of 3-methyl-4-butyrylamino-acetophenone are added in batches at -15°C to 300 ml of fuming nitric acid with stirring, and stirred for a further 30 minutes at -15°C. The reaction mixture is then poured onto 3 litres of ice, with stirring, the crude product precipitated is suction filtered, washed with 400 ml of water, dried and purified by recrystallisation from ethanol/diethylether (1:1).

Yield: 23.8 g (61.0% of theory),

R_f value: 0.32 (silica gel; methylene chloride),

R_f value: 0.48 (silica gel; methylene chloride/methanol = 50:1).

b) 3-Methyl-4-butyrylamino-5-nitro-1-bromoacetophenone

A solution of 16.0 g (200 mmol) of bromine in 140 ml of dioxane is added dropwise to a solution of 23.8 g (90 mmol) of 3-methyl-4-butyrylamino-5-nitro-acetophenone in 900 ml of dichloromethane at ambient temperature, with stirring, so slowly that total decolorisation of the reaction mixture occurs constantly. The mixture is then stirred for a further two hours, then the reaction mixture is evaporated to dryness in vacuo, the residue obtained is triturated with about 20 ml of dichloromethane/diethylether (1:1), suction filtered and then dried. 23g (74% of theory) of 3-methyl-4-butyrylamino-5-nitro-B-bromoacetophenone are thus obtained, still containing about 10% starting material. The product is further reacted without any more purification.

R_f value: 0.69 (silica gel; methylene chloride/methanol = 50:1)

R_f value: 0.84 (silica gel; methylene chloride/methanol = 9:1).

c) 2-Butyrylamino-3-nitro-5-(imidazo-4-yl)-toluene

A solution of 6.8 g (20 mmol) of 3-methyl-4-butyrylamino-5-nitro-2-bromoacetophenone in 20 ml of formamide is heated to 140°C for two hours. The cooled solution is then poured into about 50 ml of 1N ammonia and stirred for about 15 minutes. The crude product precipitated is suction filtered, washed with about 50 ml of water and dried. In this way, 4.4 g (75% of theory) of the product are obtained, which is further reacted without any more purification.

R_f value: 0.29 (silica gel; methylene chloride/methanol = 9:1)

d) 2-Butyrylamino-3-nitro-5-(1-methyl-imidazol-4-yl)-toluene

1.3 g (9.5 mmol) of methyl iodide are added dropwise at ambient temperature to a solution of 2.5 g (8.7 mmol) of 2-butyrylamino-3-nitro-5-(imidazol-4-yl)-toluene and 5.2g (30 mmol) of potassium carbonate dihydrate in 30 ml of dimethylsulfoxide and the mixture is then stirred for two hours. The reaction mixture is then stirred into about 150 ml of water and extracted four times with 25ml of ethylacetate. The organic extracts are washed with about 30 ml of water, dried and evaporated down. The crude product thus obtained is purified by column chromatography (300 g of silica gel, eluant: methylene chloride/methanol = 30:1).

Yield: 640 mg (24% of theory),

R_f value: 0.54 (silica gel; methylene chloride/methanol = 9:1)

e) 2-Butyrylamino-3-amino-5-(1-methyl-imidazol-4-yl)-toluene

640 mg (2.1 mmol) of 2-butyrylamino-3-nitro-5-(1-methyl-

imidazol-4-yl)-toluene are hydrogenated in 30 ml of methanol after the addition of about 200 mg of palladium/charcoal (20%) at ambient temperature under a hydrogen pressure of 5 bar. After all the hydrogen has been absorbed the catalyst is removed by filtering and the filtrate is evaporated down. The crude product obtained is further reacted without any more purification.

Yield: 600 mg (100% of theory),

R_f value: 0.23 (silica gel; methylene chloride/methanol = 9:1)

f) 2-n-Propyl-4-methyl-6-(1-methyl-imidazol-4-yl)-benzimidazole

600 mg (2.1 mmol) of 2-butyrylamino-3-amino-5-(1-methyl-imidazol-4-yl)-toluene are refluxed for one hour in 10ml of glacial acetic acid. Then the mixture is evaporated to dryness in vacuo, the residue is mixed with about 15 ml of water, made alkaline with ammonia and extracted four times with about 10 ml of ethylacetate. The organic extracts are washed with about 15 ml of water, dried and finally evaporated down. The crude product thus obtained is further reacted without any more purification.

Yield: 420 mg (79% of theory),

R_f value: 0.37 (silica gel; methylene chloride/methanol = 9:1)

g) Tert.butyl-4'-[(2-n-propyl-4-methyl-6-(1-methyl-imidazol-4-yl)-benzimidazol-1-yl)methyl]-biphenyl-2-carboxylate

280 mg (0.8 mmol) of tert.butyl-4'-bromomethyl-biphenyl-2-carboxylate are added to a solution of 200 mg (0.79 mmol) of 2-n-propyl-4-methyl-6-(1-methyl-imidazol-4-yl)-benzimidazole and 90 mg (0.8 mmol) of potassium tert.butoxide in 5 ml of dimethylsulfoxide and the mixture is stirred for 90 minutes at ambient

temperature. The mixture is then stirred into about 40 ml of water and extracted four times with about 10 ml of ethylacetate. The organic extracts are washed with 10 ml of water, dried and evaporated to dryness. The crude product thus obtained is purified by column chromatography (100 g silica gel, eluant: dichloromethane/methanol = 30:1).

Yield: 230 mg (56% of theory),

R_f value: 0.61 (silica gel; methylene chloride/methanol = 9:1)

h) 4'-[2-n-Propyl-4-methyl-6-(1-methyl-imidazol-4-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid

A solution of 230 mg (0.44 mmol) of tert.butyl-4'-[(2-n-propyl-4-methyl-6-(1-methyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and 2 ml of trifluoroacetic acid in 10 ml of dichloromethane was stirred overnight at ambient temperature and then evaporated to dryness. The residue was dissolved in about 5 ml of dilute sodium hydroxide solution, the solution was neutralized with acetic acid, the precipitate was suction filtered, washed with water and dried,

Yield: 120 mg (59% of theory);

Melting point: 293-295°C

R_f value: 0.39 (silica gel; methylene chloride/methanol = 9:1)

The following compounds are obtained analogously to Example 75:

4'-[(2-n-propyl-4-methyl-6-(1-ethyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(1-n-hexyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(1-benzyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(1-isopropyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(1-cyclohexyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Example 76

4'-[(2-n-Propyl-4-methyl-6-(1-methyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-
4-methyl-6-(1-methyl-imidazol-4-yl)-benzimidazol-1-yl)-
methyl]-2-cyano-biphenyl and sodium azide in
dimethylformamide.

Yield: 24% of theory,

Melting point: 255-257°C

R_f-value: 0.24 (silica gel; methylene chloride/methanol =
9:1)

C₂₉H₂₄N₈ x H₂O (506.62)

Calculated: C 68.75 H 5.97 N 22.12

Found: 68.90 5.97 22.03

The following compounds are obtained analogously to
Example 76:

4'-[(2-n-propyl-4-methyl-6-(1-ethyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[(2-n-propyl-4-methyl-6-(1-n-hexyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(1-benzyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

4'-[(2-n-propyl-4-methyl-6-(1-isopropyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

4'-[(2-n-propyl-4-methyl-6-(1-cyclohexyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Example 77

4'-[2-Ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 21% of theory

Melting point: amorphous

R_f-value: 0.27 (silica gel; methylene chloride/ethanol = 9:1)

C₃₁H₃₀N₈ (514.64)

Calculated: C 72.35 H 5.88 N 21.78

Found: 72.01 5.82 21.44

Example 78

4'-[(2-n-Propyl-4-methyl-6-(8-methyl-imidazo-[1,2-a]-pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-methyl-6-(8-methyl-imidazo-[1,2-a]-pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 87% of theory

Melting point: 295-297°C

R_f-value: 0.34 (silica gel; methylene chloride/ethanol = 9:1)

C₃₃H₃₀N₄O₂ x H₂O (532.65)

Calculated: C 74.41 H 6.05 N 10.52

Found: 74.81 6.05 10.43

Example 79

4'-[(2-n-Propyl-4-methyl-6-(2-pyridyl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-(2-pyridyl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 56% of theory,

Melting point: from 136°C (decomp.)

C₃₀H₂₇N₇ x 0.5 H₂O (494.60)

Calculated: C 72.85 H 5.71 N 19.83

Found: 72.45 6.01 19.83

Example 80

4'-[(2-n-Propyl-4-methyl-6-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 19% of theory,

Melting point: amorphous

R_f-value: 0.36 (silica gel; methylene chloride/ethanol = 9:1)

C₃₃H₃₀N₈ (538.61)

mass spectrum: m/e = 538

Example 81

4'-[(2-Ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 50% of theory,

Melting point: > 300°C

R_f-value: 0.16 (silica gel; methylene chloride/ethanol = 9:1)

Example 82

4'-[(2-n-Propyl-4-methyl-6-(1-isopropyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-methyl-6-(1-isopropyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylate and trifluoroacetic acid in methylene chloride.

Yield: 84% of theory,

Melting point: 285-286°C

R_f-value: 0.55 (silica gel; methylene chloride/methanol = 9:1)

Example 83

4'-[(2-n-Propyl-4-methyl-6-(1-isopropyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-(1-isopropyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Yield: 18% of theory

Melting point: amorphous

R_f-value: 0.29 (silica gel; methylene chloride/methanol = 9:1)

C₃₁H₃₂N₈ (516.66)

Mass spectrum: m/e = 516

Example 84

4'-[(2-n-Propyl-4-methyl-6-(1-n-hexyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-methyl-6-(1-n-hexyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl and trifluoroacetic acid in methylene chloride.

Example 85

4'-[(2-n-Propyl-4-methyl-6-(1-benzyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl-2-carboxylic acid

Prepared analogously to Example 1 from tert.butyl 4'-[(2-n-propyl-4-methyl-6-(1-benzyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-biphenyl and trifluoroacetic acid in methylene chloride.

Example 86

4'-[(2-n-Propyl-4-methyl-6-(1-n-hexyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-(1-n-hexyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

Example 87

4'-[(2-n-Propyl-4-methyl-6-(1-benzyl-imidazol-4-yl)-
benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl

Prepared analogously to Example 10 from 4'-[(2-n-propyl-4-methyl-6-(1-benzyl-imidazol-4-yl)-benzimidazol-1-yl)-methyl]-2-cyano-biphenyl and sodium azide in dimethylformamide.

In the Examples of Pharmaceutical Formulations which follow, any suitable compound of formula I, particularly those compounds wherein R_4 represents a carboxy- or 1H-tetrazolyl group, may be used as the active substance:

Examwle 1

Ampoules containing 50 mg of active substance per 5 ml

Composition:

| | |
|--------------------------------|-------|
| Active substance | 50 mg |
| KH_2PO_4 | 2 mg |
| $Na_2HPO_4 \times 2H_2O$ | 50 mg |
| NaCl | 12 mg |
| Water for injections <u>ad</u> | 5 ml |

Preparation:

The buffer substances and isotonic substance are dissolved in some of the water. The active substance is added and, once it has been completely dissolved, water is added to make up the required volume.

Example II

Ampoules containing 100 mg of active substance per 5 ml

Composition:

| | |
|---|---------|
| Active substance | 100 mg |
| Methyl glucamine | 35 mg |
| Glycofurol | 1000 mg |
| Polyethyleneglycol-polypropylene-glycol Block polymer | 250 mg |
| Water for injections <u>ad</u> | 5 ml |

Preparation:

Methyl glucamine is dissolved in some of the water and the active substance is dissolved with stirring and heating. After the addition of solvents (glycolfurol and polyethyleneglycol - polypropyleneglycol block copolymer), water is added to make up the desired volume.

Example III

Tablets containing 50 mg of active substance

Composition:

| | |
|----------------------|---------------|
| Active substance | 50.0 mg |
| Calcium phosphate | 70.0 mg |
| Lactose | 40.0 mg |
| Corn starch | 35.0 mg |
| Polyvinylpyrrolidone | 3.5 mg |
| Magnesium stearate | <u>1.5 mg</u> |
| | 200.0 mg |

Preparation:

The active substance, CaHPO_4 , lactose and corn starch are uniformly moistened with an aqueous PVP solution. The mass is gassed through a 2 mm screen, dried at 50°C in a circulating air dryer and screened again.

After the lubricant (magnesium stearate) has been added, the granules are compressed in a tablet making machine.

Example IV

Coated tablets containing 50 mg of active substance

Composition:

| | |
|--------------------|---------------|
| Active substance | 50.0 mg |
| Lysine | 25.0 mg |
| Lactose | 60.0 mg |
| Corn starch | 34.0 g |
| Gelatin | 10.0 mg |
| Magnesium stearate | <u>1.0 mg</u> |
| | 180.0 mg |

Preparation:

The active substance is mixed with the excipients and moistened with an aqueous gelatin solution. After screening and drying the granules are mixed with magnesium stearate and compressed to form tablet cores.

The cores thus produced are covered with a coating by known methods. A colouring may be added to the coating suspension or solution.

Example V

Coated tablets containing 100 mg of active substance

Composition:

| | |
|----------------------------|---------------|
| Active substance | 100.0 mg |
| Lysine | 50.0 mg |
| Lactose | 86.0 mg |
| Corn starch | 50.0 mg |
| Polyvinylpyrrolidone | 2.8 mg |
| Microcrystalline cellulose | 00.0 mg |
| Magnesium stearate | <u>1.2 mg</u> |
| | 350.0 mg |

Preparation:

The active substance is mixed with the excipients and moistened with an aqueous FVP solution. The moist mass is passed through a 1.5 mm screen and dried at 45°C. After drying, it is screened again and the magnesium stearate is added. This mixture is compressed into cores.

The cores thus produced are covered with a coating by known methods. Colourings may be added to the coating suspension or solution.

Example VI

Capsules containing 250 mg of active substance

Composition:

| | |
|--------------------|---------------|
| Active substance | 250.0 mg |
| Corn starch | 68.5 mg |
| Magnesium stearate | <u>1.5 mg</u> |
| | 320.0 mg |

Preparation:

The active substance and corn starch are mixed together and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The final mixture is packed into size 1 hard gelatine capsules.

Example VII

Oral suspension containing 50 mg of active substance per 5 ml

Composition:

| | |
|-----------------------|----------|
| Active substance | 50.0 mg |
| Hydroxyethylcellulose | 50.0 mg |
| Sorbic acid | 5.0 mg |
| 70% sorbitol | 600.0 mg |
| Glycerol | 200.0 mg |
| Flavouring | 15.0 mg |
| Water ad | 5.0 ml |

Preparation:

Distilled water is heated to 70°C. Hydroxyethyl-cellulose is dissolved therein with stirring. With the addition of sorbitol solution and glycerol the mixture is cooled to ambient temperature. At ambient temperature, sorbic acid, flavouring and active substance are added. The suspension is evacuated with stirring to remove any air. One dose of 50 mg is contained in 5.0 ml.

Example VIII

Suppositories containing 100 mg of active substance

Composition:


| | |
|-----------------------|------------------|
| Active substance | 100.0 mg |
| Solid fat (e.g. lard) | <u>1600.0 mg</u> |
| | 1700.0 mg |

Preparation:

The hard fat Es melted. At 40°C the ground active
substanca is homogeneously dispersed in the melt. It is
cooled to 38°C and poured into slightly chilled
suppository moulds.

patent Claims

1. **Compounds of formula**



(wherein

R₁ in the 4-position represents a fluorine, chlorine or bromine atom or a C₁₋₄-alkyl, cycloalkyl, fluoromethyl, difluoromethyl or trifluoromethyl group, and

R₂ represents a C₃₋₅-alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R₂ may represent a C₂₋₅-alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

or R₂ represents a C_n-alkylsulphonyloxy group, a benzenesulphonyloxy or phenylalkanesulphonyloxy group,

an acylamino group optionally substituted at the nitrogen atom by a C_n-alkyl group or by a phenyl, cycloalkyl, phenylalkyl, cycloalkylalkyl, bicyclohexyl or biphenyl group, in which the acyl group is a C₁₋₇-alkanoyl group, a C₂₋₄(alkoxycarbonyl) group, a C₁₋₄-alkylsulphonyl group, a benzoyl, benzenesulphonyl, phenylalkanesulphonyl, naphthalenesulphonyl, cycloalkylcarbonyl, phenylalkanoyl or cycloalkylalkanoyl group, in which the above-mentioned phenyl nuclei may

each be mono- or di-substituted by a fluorine, chlorine or bromine atom or by a methyl or methoxy group and the substituents may be identical or different,

a phthalimino, homophthalimino, 2-carboxyphenylcarbonyl-amino or 2-carboxyphenylmethylamino group, in which a carbonyl group in a phthalimino group may be replaced by a methylene, alkyl-methylene or dialkyl-methylene group, and a methylene group in a homophthalimino group may be substituted by one or two alkyl groups, and additionally the above-mentioned phenyl nuclei may be totally or partially hydrogenated and may be mono- or di-substituted by alkyl or alkoxy groups whilst the substituents may be identical or different,

a 5-, 6- or 7-membered alkyleneimino or alkenyleneimino group optionally substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group, in which a methylene group may be replaced by a carbonyl or sulphonyl group,

a bicycloalkane-2,3-dicarboxylic acid imino or bicycloalkene-2,3-dicarboxylic acid imino group, wherein the bicycloalkane and bicycloalkene moieties may each contain 9 or 10 carbon atoms, may be substituted by 1, 2 or 3 methyl groups and may have an endomethylene group replaced by an oxygen atom,

an amidino group optionally substituted by one or two C₁₋₆ alkyl groups,

a glutaric acid imino group wherein the n-propylene group may be perfluorinated, or may be substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group,

a maleic acid imido group optionally mono- or di-



substituted by an alkyl or phenyl group, whilst the **substituents** may be identical or different,

a 5-membered heteroaromatic ring bound via a carbon atom or via an imino group and containing an imino group, an oxygen or sulphur atom, or an imino group plus an oxygen, sulphur or nitrogen atom, or R_2 may represent a 6-membered heteroaromatic ring bound via a carbon atom and containing 1 or 2 nitrogen atoms, whilst the abovementioned heteroaromatic rings may be substituted in the carbon structure by a C_{1-6} alkyl or by a phenylalkyl group, and an n-propylene or n-butylene group may be linked to the 6-membered heteroaromatic rings via two carbon atoms, or a 1,3-butadienyl group may be linked to both the 5-membered and 6-membered heteroaromatic rings via two adjacent carbon atoms or an n-butylene or 1,3-butadienyl group is linked thereto via an imino group and an adjacent carbon atom and, in an anellated pyridine ring thus formed, a methine group may be replaced by a nitrogen atom and a vinylene group in the 3-, 4-position relative to the nitrogen atom of the pyridine ring formed may be replaced by a sulphur atom or in an anellated phenyl ring thus formed, one or two methine groups may be replaced by N-atoms, whilst additionally the above-mentioned fused aromatic or heteroaromatic rings may be monosubstituted in the carbon structure by a fluorine, chlorine or bromine atom or by an alkyl, alkoxy, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, alkanoyl, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group or may be disubstituted by fluorine or chlorine atoms or by methyl, methoxy or hydroxy groups, and two methyl substituents in the 1,2-position relative to each other may be linked by a methylene or ethylene bridge and an

-NH- group optionally present in an imidazole ring may be substituted by a C₁₋₆-alkyl group, by a phenylalkyl group or by a cycloalkyl group, or

a pyrrolidine, piperidine or pyridine ring bound via a carbon atom, in which a phenyl group may be condensed onto the pyridine ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group,

an imidazolidinedione group optionally substituted by an alkyl, phenylalkyl, tetramethylene, pentamethylene or hexamethylene group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by an optionally phenyl substituted alkyl group and additionally, in the carbon skeleton, by 1 or 2 alkyl groups,

an R₇-NR₆-CO-NR₅- group

(wherein

R₅ represents a hydrogen atom or a C₁₋₈-alkyl, C₅₋₇ cycloalkyl or phenylalkyl group,

R₆ represents a hydrogen atom or a C₁₋₈-alkyl, C₃₋₅-alkenyl, phenyl, phenylalkyl or C₅₋₇-cycloalkyl group,

R₇ represents a hydrogen atom or a C₁₋₆-alkyl group, or

one of the groups R₅, R₆ or R₇ may also represent a bicyclohexyl or biphenyl group, or

R₆ and R₇ together with the nitrogen atom between them represent an unbranched C₄₋₆-alkyleneimino group or a



morpholino group, or

R_5 and R_6 together represent a C_{n-} -alkylene group),

or R_2 may represent a 1H,3H-quinazolin-2,4-dion-3-yl or pentamethylene-oxazolin-2-yl group,

or, if R_4 represents a 1H-tetrazolyl group, R_2 may also represent a 2-(imidazol-1-yl)-ethoxy group; or

R_1 represents a hydrogen atom or in the 5-, 6- or 7-position R_1 represents a fluorine, chlorine or bromine atom or a C_{1-4} -alkyl, fluoromethyl, difluoromethyl or trifluoromethyl group, and

R_2 represents a 5-membered heteroaromatic ring bound via a carbon atom or via an imino group and containing an imino group, an oxygen or sulphur atom or, an imino group plus an oxygen, sulphur or nitrogen atom, or R_2 represents a 6-membered heteroaromatic ring bound via a carbon atom and containing 1 or 2 nitrogen atoms, whilst the above mentioned heteroaromatic rings may be substituted in the carbon skeleton by a C_{1-6} alkyl or by a phenylalkyl group and an n-propylene or n-butylene group may be linked to the 6-membered heteroaromatic rings via two carbon atoms, or a 1,3-butadienyl group may be linked via two adjacent carbon atoms to both the 5-membered and 6-membered heteroaromatic rings or an n-butylene or 1,3-butadienyl group may be linked to said 5-membered and 6-membered heteroaromatic rings via an imino group and an adjacent carbon atom and, in an anellated pyridine ring thus formed, a methine group may be replaced by a nitrogen atom and a vinylene group in the 3-, 4-position relative to the nitrogen atom of the pyridine ring formed may be replaced by a sulphur atom or in an anellated phenyl ring thus formed, one or two methine groups may be replaced by N-atoms, whilst

additionally the above-mentioned **fused** aromatic or heteroaromatic rings may be monosubstituted **on** the carbon skeleton by a fluorine, chlorine or bromine atom or by an alkyl, alkoxy, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, alkanoyl, **aminosulphonyl**, alkylaminosulphonyl or dialkylamino-sulphonyl group or may be disubstituted by fluorine or chlorine atoms or by methyl, methoxy or hydroxy groups, and two methyl substituents in the **1,2-position** relative to each other may be linked by a methylene or ethylene bridge and an -NH- group optionally present in an imidazole ring may be substituted by a **C₁₋₆-alkyl** group, by a phenylalkyl group or by a cycloalkyl group, with the provisos that where

- (i) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy, **tert.butoxycarbonyl**, cyano or **1H-tetrazolyl** group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where *
- (ii) R_1 represents a hydrogen atom, R_3 represents a methyl, ethyl or n-butyl group and R_4 represents a cyano or **1H-tetrazolyl** group, then R_2 cannot represent a benzoxazol-2-yl or **1-methyl-benzimidazol-2-yl** group in the 6-position, and where
- (iii) R_1 represents a hydrogen atom, R_3 represents an **n-butyl** group and R_4 represents a carboxy or **tert.butoxycarbonyl** group, then R_2 cannot represent a **benzimidazol-2-yl** group in the 6-position, and where



(iv) R_1 represents a hydrogen atom, R_3 represents an *n*-propyl group and R_4 represents a carboxy or **tert.butoxycarbonyl** group, then R_2 cannot represent a 3-methyl-imidazo-(4,5-b)pyridin-2-yl or 3-n-hexyl-imidazo(4,5-b)pyridin-2-yl group in the 6-position, a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a methyl or trifluoromethyl group, by a **fluorine** or chlorine atom or in the 6-position by a methyl group, or a 1-n-butyl-benzimidazol-2-yl group in the 6-position, and where

(v) R_1 represents a hydrogen atom, R_3 represents an *n*-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a **bromine** atom or by a methoxy group, a 1-n-butyl-5-trifluoromethyl-benzimidazol-2-yl or 1-n-hexyl-5-methyl-benzimidazol-2-yl group in the 6-position, and where

(vi) R_1 represents a hydrogen atom, R_3 represents an ethyl or *n*-butyl group and R_4 represents a carboxy or **tert.butoxycarbonyl** group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position,

or R_2 may represent a pyrrolidina, piperidine or pyridine ring **bound** via a carbon atom, in which a phenyl group may be condensed onto the pyridine ring via 2 adjacent carbon **atoms** and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group;

R_1 represents a hydrogen atom or a **C₁₋₅-alkyl** group in which a methylene group **may** be replaced by a sulphur atom, or R_3 may represent a **C₃₋₅cycloalkyl** group; and



R₄ represents a carboxy, cyano, 1H-tetrazolyl, 1-triphenylmethyldetrazolyl, C₂₋₅(alkoxycarbonyl), alkanesulphonylaminocarbonyl, arylsulphonylaminocarbonyl or trifluoromethanesulphonylaminocarbonyl group;

wherein, unless otherwise specified, each alkanoyl, alkyl or alkoxy moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms)

and the isomers, isomer mixtures and addition salts thereof.

2. Compounds of general formula I as claimed in claim 1,



(wherein

R₁ in the 4-position represents a fluorine, chlorine or bromine atom, a C₁₋₃-alkyl group or a cycloalkyl, fluoromethyl, difluoromethyl or trifluoromethyl group, and

R₂ represents a C₃₋₅-alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R₂ represents a C₂₋₅-alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

an acylamino group optionally substituted at the nitrogen atom by a C₁₋₅-alkyl group, wherein the acyl group is a C₂₋₇-alkanoyl group, a C₂₋₄(alkoxycarbonyl) group, a C₁₋₃-alkylsulphonyl group or a benzenesulphonyl group,

a phthalimino or homophthalimino group, wherein a carbonyl group in a phthalimino group may be replaced by a methylene group and a methylene in a homophthalimino group may be substituted by one or two alkyl groups,

a 5-, 6- or 7-membered alkyleneimino or alkenyleneimino group, optionally substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group, wherein a methylene group may be replaced by a carbonyl or sulphonyl group,

a glutaric acid imino group wherein the n-propylene group may be perfluorinated, or may be substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group,

a maleic acid imido group optionally mono- or disubstituted by an alkyl or phenyl group, whilst the

substituents may be identical or different,

an amidino group optionally substituted by one or two C_{1-4} alkyl groups,

a benzimidazol-2-yl group optionally substituted in the 1-position by C_{1-6} -alkyl or a cycloalkyl group and optionally substituted in the phenyl nucleus by a fluorine atom or by a methyl or trifluoromethyl group,

or R_2 represents an imidazo[2,1-b]thiazol-6-yl, imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]-pyridazin-2-yl, imidazo[4,5-c]pyridin-2-yl, purin-8-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl or imidazo[4,5-d]pyridazin-2-yl group, or a carbon attached pyrrolidine, piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group,

a carbon attached imidazolyl group optionally substituted in the 1-position by a C_{1-3} -alkyl group or by a benzyl group, and which may also be substituted in the carbon skeleton by a C_{1-3} -alkyl group,

an imidazolidindione group optionally substituted by an alkyl, phenylalkyl, tetramethylene, pentamethybenzene or hexamethylene group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by a methyl or benzyk group,

an R_7 -NR₆-CO-NR₅- group

(wherein

R₅ represents a hydrogen atom, a C₁₋₃-alkyl group, a cyclohexyl or benzyl group,

R₆ represents a hydrogen atom, a C_n-alkyl group, an allyl, cyclohexyl, benzyl or phenyl group,

R₇ represents a hydrogen atom or a C_n-alkyl group or

R₆ and R₇ together with the nitrogen atom between them represent an unbranched C₄₋₆-alkyleneimino group or a morpholino group or

R₅ and R₆ together represent a C_n-alkylene group);

or R₁ represents a hydrogen atom or in the 5-, 6- or 7-position R₁ represents a fluorine, chlorine or bromine atom or a C₁₋₄-alkyl or a trifluoromethyl group, and

R₂ represents a benzimidazol-2-yl group optionally substituted in the 1-position by a C₁₋₆-alkyl group or by a cycloalkyl group, and optionally substituted in the phenyl nucleus by a fluorine atom or by a methyl or trifluoromethyl group,

or R₂ represents an imidazo[2,1-b]thiazol-6-yl, imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]-pyridazin-2-yl, imidazo[4,5-c]-pyridin-2-yl, purin-8-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl or imidazo[4,5-d]-pyridazin-2-yl group, or a carbon attached pyrrolidine,

piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine ring via 2 adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group, or a carbon attached imidazolyl group optionally substituted in the 1-position by a C_{1-3} alkyl group or by a benzyl group which may also be substituted in the carbon skeleton by a C_{1-3} alkyl group, with the proviso that where

- (i) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy or 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where
- (ii) R_1 represents a hydrogen atom, R_3 represents a methyl, ethyl or n-butyl group and R_4 represents a 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position, and where
- (iii) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a benzimidazol-2-yl group in the 6-position, and where
- (iv) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a fluorine atom, by a methyl or trifluoromethyl group or in the 6-position by a methyl group, or a 1-n-butyl-benzimidazol-2-yl group in the 6-position, and where



(v) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-n-butyl-5-trifluoromethyl-benzimidazol-2-yl or 1-n-hexyl-5-methyl-benzimidazol-2-yl group in the 6-position, and where

(vi) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position;

R_3 represents a C_{1-5} -alkyl group or a C_{3-5} -cycloalkyl group; and

R_4 represents a carboxy or 1H-tetrazolyl group;

wherein, unless otherwise specified, each alkanoyl, alkyl or alkoxy moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms)

and the isomers, isomer mixtures and addition salts thereof.

3. Compounds of formula I as claimed in claim 1,

(wherein

R_1 in the 4-position represents a chlorine atom, or a C_{1-3} -alkyl or a trifluoromethyl group, and

R_2 represents a C_{3-5} -alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R_2 represents a C_{2-5} -alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl



group,

a C_{2-5} (alkanoyl)amino or N-benzenesulphonyl-methylamino group,

a phthalimino or homophthalimino group, wherein a carbonyl group in a phthalimino group may be replaced by a methylene group,

a 5-, 6- or 7-membered alkyleneimino group wherein a methylene group is replaced by a carbonyl or sulphonyl group,

a glutaric acid imino group wherein the n-propylene group may be substituted by one or two alkyl groups or by a tetramethylene or pentamethylene group,

a maleic acid imido group optionally mono- or disubstituted by an alkyl or phenyl group, whilst the substituents may be identical or different,

a benzimidazol-2-yl group optionally substituted in the 1-position by a C_{1-6} -alkyl group or by a cycloalkyl group, and optionally substituted in the phenyl nucleus by a fluorine atom or by a methyl or trifluoromethyl group,

or R_2 represents an imidazo[2,1-b]thiazol-6-yl, imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]-pyridazin-2-yl, imidazo[4,5-c]pyridin-2-yl, purin-8-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl or imidazo[4,5-d]pyridazin-2-yl group, or a carbon attached pyrrolidine, piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine

ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group,

or R_2 represents an imidazol-4-yl group substituted in the 1-position by a $C_{1,3}$ alkyl group or by a benzyl group which may also be substituted in the carbon skeleton by a $C_{1,3}$ alkyl group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by a methyl or benzyl group,

an $R_7-NR_6-CO-NR_5-$ group

(wherein

R_5 represents a hydrogen atom or a $C_{1,6}$ -alkyl, cyclohexyl or benzyl group,

R_6 represents a hydrogen atom, a $C_{1,6}$ -alkyl group or an allyl, cyclohexyl, benzyl or phenyl group,

R_7 represents a hydrogen atom or a $C_{1,3}$ -alkyl group or

R_6 and R_7 together with the nitrogen atom between them represent an unbranched $C_{4,6}$ -alkyleneimino group or a morpholino group or

R_5 and R_6 together represent a $C_{2,3}$ -alkylene group);

or R_1 represents a hydrogen atom or in the 5-, 6- or 7-position R_1 represents a $C_{1,4}$ -alkyl group or a trifluaromethyl group, and

R_2 represents a benzimidazol-2-yl group optionally substituted in the 1-position by a $C_{1,6}$ -alkyl group or by

a cycloalkyl group and optionally substituted in the phenyl nucleus by a fluorine atom or by a methyl or trifluoromethyl group,

or R_2 represents an imidazo[2,1-b]thiazol-6-yl, imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]-pyridazin-2-yl, imidazo[4,5-c]-pyridin-2-yl, purin-8-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl or imidazo[4,5-d]pyridazin-2-yl group, or a carbon attached pyrrolidine, piperidine or pyridine ring in which a phenyl group may be condensed onto the pyridine ring via two adjacent carbon atoms and a methylene group adjacent to the N-atom in a pyrrolidine or piperidine ring may be replaced by a carbonyl group, or an imidazol-4-yl group substituted in the 1-position by a C_{1-3} alkyl group or by a benzyl group which may also be substituted in the carbon skeleton by a C_{1-3} alkyl group, with the proviso that where

- (i) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy or 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where
- (ii) R_1 represents a hydrogen atom, R_3 represents a methyl, ethyl or n-butyl group and R_4 represents a 1H-tetrazolyl group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position, and where



- (iii) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a benzimidazol-2-yl group in the 6-position, and where
- (iv) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a fluorine atom, by a methyl or trifluoromethyl group or in the 6-position by a methyl group, or a 1-n-butyl-benzimidazol-2-yl group in the 6-position, and where
- (v) R_1 represents a hydrogen atom, R_3 represents an n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-n-butyl-5-trifluoromethyl-benzimidazol-2-yl or 1-n-hexyl-5-methyl-benzimidazol-2-yl group in the 6-position, and where
- (vi) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position;

R_3 represents a C_{1-5} -alkyl group or a C_{3-5} -cycloalkyl group; and

R_4 represents a carboxy or 1H-tetrazolyl group;

wherein, unless otherwise specified, each alkanoyl, alkyl or alkoxy moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms)

and the isomers, isomer mixtures and addition salts



thereof.

4. Compounds of formula I as claimed in claim 1,

(wherein

R, in the 4-position represents a chlorine atom or a methyl group, and

R₂ represents a C_{3,5}-alkoxy group substituted in the 3-, 4- or 5-position by an imidazolyl group, or R₂ represents a C_{2,5}-alkoxy group substituted in the 2-, 3-, 4- or 5-position by a benzimidazolyl or tetrahydrobenzimidazolyl group,

a C_{2,5}(alkanoyl)amino group or N-benzenesulphonyl-methylamino group,

a phthalimino or homophthalimino group, wherein a carbonyl group in a phthalimino group may be replaced by a methylene group,

a 5-, 6- or 7-membered alkyleneimino group, wherein a methylene group is replaced by a carbonyl or sulphonyl group,

a maleic acid imido group optionally mono- or disubstituted by an alkyl or phenyl group, whilst the substituents may be identical or different,

a benzimidazol-2-yl group optionally substituted in the 1-position by a C_{1,3}-alkyl group and optionally substituted in the phenyl nucleus by a fluorine atom,

or R₂ represents an imidazo[1,2-a]-pyridin-2-yl group, 5,6,7,8-tetrahydro-imidazo[1,2-a]-pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl or imidazo[2,1-b]thiazol-6-

yl group,

an imidazol-4-yl group substituted in the 1-position by a C₁₋₃ alkyl group,

a pyridazin-3-one or dihydro-pyridazin-3-one group which may be substituted in the 2-position by a methyl or benzyl group; or

R₁ represents a hydrogen atom or in the 5-, 6- or 7-position R₁ represents a methyl group, and

R₂ represents a benzimidazol-2-yl group optionally substituted in the 1-position by a C₁₋₃-alkyl group, and optionally substituted in the phenyl nucleus by a fluorine atom,

or R₂ represents an imidazo[1,2-a]pyridin-2-yl group, or an imidazol-4-yl group substituted in the 1-position by a C₁₋₃ alkyl group, with the proviso that where

- (i) R₁ represents a hydrogen atom, R₃ represents an n-propyl group and R₄ represents a carboxy or 1H-tetrazolyl group, then R₂ cannot represent a 1-methyl-benzimidazol-2-yl group in the 5- or 6-position, and where
- (ii) R₁ represents a hydrogen atom, R₃ represents a methyl, ethyl or n-butyl group and R₄ represents a 1H-tetrazolyl group, then R₂ cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position, and where
- (iii) R₁ represents a hydrogen atom, R₃ represents an n-butyl group and R₄ represents a carboxy group, then R₂ cannot represent a benzimidazol-2-yl group in the 6-position, and where



(iv) R_1 represents a hydrogen atom, R_3 represents an n-propyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methyl-benzimidazol-2-yl group in the 6-position substituted in the 5-position by a fluorine atom, and where

(v) R_1 represents a hydrogen atom, R_3 represents an ethyl or n-butyl group and R_4 represents a carboxy group, then R_2 cannot represent a 1-methylbenzimidazol-2-yl group in the 6-position;

R_3 represents a C_{1-5} -alkyl group or a C_{3-5} -cycloalkyl group; and

R_4 represents a carboxy or 1H-tetrazolyl group;

wherein, unless otherwise specified, each alkanoyl, alkyl or alkoxy moiety contains 1 to 3 carbon atoms and each cycloalkyl moiety contains 3 to 7 carbon atoms)

and the isomers, isomer mixtures and addition salts thereof.

5. Compounds of formula I as claimed in claim 1,

(wherein

R_1 in the 4-position represents a chlorine atom or a methyl group, and



R₂ represents a benzimidazol-2-yl group optionally substituted in the **1-position** by a **C₁₋₃-alkyl** group and optionally substituted in the phenyl nucleus by a **fluorine** atom, or

R₂ represents an imidazo[1,2-a]pyridin-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]-pyridin-2-yl, imidazo[1,2-a]-pyrimidin-2-yl or imidazo[2,1-b]thiazol-6-yl group, and

R₃ represents a **C₁₋₅-alkyl** group or a **C₃₋₅-cycloalkyl** group, and

R₄ represents a carboxy or **1H-tetrazolyl** group)

and the isomers, isomer mixtures and addition salts thereof.

6. A compound as claimed in claim 1 being:

4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-Biphenyl;

4'-[[2-n-propyl-4-methyl-6-(1-oxo-isoindolin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-propyl-4-methyl-6-(butanesultam-1-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4'-[[2-n-butyl-6-(2,3-dimethylmaleic acid imino)-4-methylbenzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;



4' - [[2-n-butyl-6-(isopropylcarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4' - [[2-n-butyl-4-methyl-6-(morpholinocarbonylamino)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4' - [[2-n-butyl-6-(cyclohexylaminocarbonylamino)-4-methyl-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4' - [[2-cyclopropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4' - [[2-n-propyl-4-methyl-6-(1-methyl-5-fluoro-benzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4' - [[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyrimidin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4' - [[2-n-propyl-4-methyl-6-(4,5,6,7-tetrahydroimidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

4' - [[2-n-propyl-4-methyl-6-(4,5,6,7-tetrahydroimidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4' - [[2-n-propyl-4-chloro-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-2-(1H-tetrazol-5-yl)-biphenyl;

4' - [[2-n-propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;



4' - [[2-ethyl-4-methyl-6-(butanesultam-1-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-butyl-4-methyl-6-(1-methylbenzimidazol-2-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-propyl-6-(imidazo[1,2-a]pyridin-2-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl) -
benzimidazol-1-yl] -methyl] -biphenyl-2-carboxylic acid;

4' - [[2-n-propyl-4-methyl-6-(imidazo[1,2-a]pyridin-2-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-propyl-4-methyl-6-(imidazo[2,1-b]thiazol-6-yl) -
benzimidazol-1-yl] -methyl] -2- (1H-tetrazol-5-yl) -
biphenyl;

4' - [[2-n-propyl-4-methyl-6-(1-methyl-6-fluoro-
benzimidazol-2-yl) -benzimidazol-1-yl] -methyl] -biphenyl-
2-carboxylic acid; and

4' - [[2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-
a]pyridin-2-yl) -benzimidazol-1-yl] -methyl] -biphenyl-2-
carboxylic acid;

or an isomer, isomer mixture or addition salt thereof.

7. A compound as claimed in claim 1 being:

4' - [[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl) -
benzimidazol-1-yl] -methyl] -biphenyl-2-carboxylic acid;




4'-[[2-ethyl-4-methyl-6-(5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid;

or an isomer, isomer mixture or addition salt thereof.

8. A pharmaceutical composition containing a compound of formula I according to any one of claims 1 to 7 or a physiologically acceptable addition salt thereof together with one or more inert carriers or diluents.


9. A process for preparing the compounds as claimed in any one of claims 1 to 7, said process comprising at least one of the following steps:

a) cyclising compound of formula II



(wherein


R₁ and R₂ are as defined in any one of claims 1 to 7, one of the groups X, or Y, represents a group of formula II(a)



II(a)

and the other group X, or Y, represents a group of the formula II(b)





II (b)

(wherein


R_3 represents a hydrogen atom or an $\text{R}_3\text{CO}-$ group, R_1 and R_4 are as defined in any one of claims 1 to 7,

Z_1 and Z_2 , which may be identical or different, represent optionally substituted amino groups or hydroxy or mercapto groups **optionally** substituted by lower alkyl groups or

Z_1 and Z_2 together represent an oxygen or sulphur atom, an optionally **C₁₋₃-alkyl** substituted imino group, an alkylenedioxy or alkylenedithio group, each having 2 or 3 carbon **atoms**))

and any corresponding N-oxide thus obtained is reduced;


b) reacting a compound of formula III



(III)

(wherein

R_1 to R_3 **are** as defined in any one of claims 1 to 7), with a biphenyl compound of **formula IV**




(IV)

(wherein

R_4 is as defined in any one of claims 1 to 7, and Z_3 represents a **nucleophilic leaving group**);




c) (to prepare compounds of formula I wherein R_4 represents a carboxy group) converting a compound of formula V



(wherein

R_1 to R_3 are as defined in any one of claims 1 to 7, and R_4' represents a group which may be converted into a carboxy group by hydrolysis, thermolysis or **hydrogenolysis**) into a corresponding carboxy compound;

d) (to prepare compounds of formula I wherein R_4 represents a **1H-tetrazolyl** group) cleaving a protecting group from a compound of formula VI




(wherein

R_1 , R_2 and R_3 are as defined in any one of claims 1 to 7; and R_4'' represents a **1H-tetrazolyl** group protected in the 1- or 3-position by a protecting group);

e) (to prepare compounds of formula I wherein R_4 represents a **1H-tetrazolyl** group) reacting a compound of formula VII






(wherein

R₁ to R₃ are as defined in any one of claims 1 to 7) with hydrazoic acid or a salt thereof;

f) (to prepare compounds of formula I wherein R₂ represents one of the imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-b]pyridazin-2-yl or imidazo[2,1-b]thiazol-6-yl groups mentioned in any one of claims 1 to 7) reacting a compound of formula VIII



(wherein


one of the groups A, B, C or D represents a methine group or a nitrogen atom and the remaining groups A, B, C or D represent methine groups, or

A and B each represent methine and the -C=D- moiety represents a sulphur atom,

R₉ represents a hydrogen, fluorine, chlorine or bromine atom or an alkyl, alkoxy, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkanoyl, aminosulphonyl, alkylaminosulphonyl or dialkylaminosulphonyl group, and




R_{10} represents a hydrogen, fluorine or chlorine atom or a methyl, methoxy or hydroxy group; or R_9 and R_{10} attached at adjacent ring positions together represent a propylene or n-butylene group) with a compound of formula IX



(wherein

R_1 , R_3 and R_4 are as defined in any one of claims 1 to 7 and Z_4 represents a nucleophilic leaving group);

g) (to prepare compounds of formula I wherein R_2 represents one of the benzimidazol-2-yl, imidazo[4,5-b]pyridin-2-yl, imidazo[4,5-c]pyridin-2-yl, imidazo[4,5-b]pyrazin-2-yl, imidazo[4,5-c]pyridazin-2-yl, imidazo[4,5-d]pyridazin-2-yl or purin-8-yl groups mentioned in any one of claims 1 to 7) cyclising a compound of formula X



(wherein

none, one or two of the groups A_1 , B_1 , C , or D , represents a nitrogen atom and

the remaining groups A_1 , B_1 , C , or D , represent methine groups;


R_{11} represents a hydrogen, fluosine, chlorine or bromine



atom or an alkyl, **alkoxy**, hydroxy, phenyl, nitro, amino, alkylamino, dialkylamino, alkanoylamino, cyano, **carboxy**, **alkoxycarbonyl**, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, trifluoromethyl, alkanoyl, aminosulphonyl, alkylaminosulphonyl or dialkylamino-sulphonyl group; and

R_{12} represents a hydrogen, fluorine or chlorine atom or a methyl, methoxy or hydroxy group;

one of the groups X , or Y , represents an R_{13} -NH- group and the other X , or Y , group represents a group of formula $X(a)$



$X(a)$

(wherein

R_1 , R_3 and R_4 are as defined in any one of **claims** 1- to 7; one of the groups R_{13} or R_{14} represents a hydrogen atom and the other R_{13} or R_{14} group represents a hydrogen atom, a C_{1-6} -alkyl group or a cycloalkyl group;


Z_5 and Z_6 , which may be identical or different, represent optionally substituted amino groups or hydroxy or mercapto groups optionally substituted by lower alkyl groups or

Z_5 and Z_6 together represent an **oxygen** or sulphur atom, an optionally C_{1-3} -alkyl substituted **imino** group, an **alkylenedioxy** or **alkylenedithio** group each having 2 or 3 carbon atoms),

and reducing any corresponding N-oxide thus obtained, and optionally **hydrolysing** the resulting product;



h) (to prepare compounds of formula I wherein R_2 represents a dihydro-pyridazin-3-one or pyridazin-3-one group which may be substituted in the 2-position by a C_{1-3} -alkyl group optionally substituted by a phenyl group, or in the carbon structure by one or two alkyl groups each having 1 to 3 carbon atoms) reacting a carboxylic acid of formula XII



(wherein

R_1 , R_3 and R_4 are as defined in any one of claims 1 to 7; and E represents an ethylene or ethenylene group optionally substituted by one or two C_{1-3} alkyl groups), or a reactive acid derivative thereof, with a hydrazine of formula XIII



(wherein

R_{15} represents a hydrogen atom or a C_{1-3} -alkyl group optionally substituted by a phenyl group);

i) performing the reaction of any one of steps (a) to (h) using a starting material wherein a reactive group is protected by a protecting group and subsequently removing any protecting group used;

j) resolving an isomer mixture into the separate component isomers;

k) converting a compound of formula I into an addition salt thereof or converting a salt of a compound of formula I into the compound.



10. A method **of** treatment of the human or non-human **animal** body said method **comprising** administering to said body a pharmaceutically acceptable form of a compound **of formula I as defined** in any one of claims 1 to 7 or an isomer or salt thereof.

11. A method **of** treatment as claimed in claim 10 wherein said body is suffering from hypertension, **pulmonary** diseases, cardiac insufficiency, ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), **diabetic** nephropathy, glaucoma, gastrointestinal or bladder diseases or cardiac **insufficiency** after myocardial infarction.

12. A method **of** treatment as claimed in claim 10, wherein said **body is** suffering from depression, **Alzheimer's** disease, Parkinson syndrome, **bulimia**, disorders of **cognitive function** or other **central** nervous system disorders.

13. A compound as claimed in any one of claims 1 to 7 **substantially** as disclosed in any one of the **Examples**.

Dated this 29th day of July 1994

DR KARL THOMAE GmbH
by their Patent Attorneys
CALLINAN LAWRIE

